var title_f27_39_28272="Parotid enlargement";
var content_f27_39_28272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enlargement of L parotid gland in Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left parotid gland is visibly swollen just at the angle of the left mandible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Creamer, MD, MRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28272=[""].join("\n");
var outline_f27_39_28272=null;
var title_f27_39_28273="AML FAB M5";
var content_f27_39_28273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute monoblastic leukemia (M5)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with acute monoblastic leukemia (FAB classification M5). (Wright-Giemsa stain.) The two monoblasts on the left have abundant cytoplasm with numerous azurophilic granules. The nuclear membrane of the promonocyte on the right has delicate folds and creases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28273=[""].join("\n");
var outline_f27_39_28273=null;
var title_f27_39_28274="Talc (sterile): Drug information";
var content_f27_39_28274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Talc (sterile): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/55/39795?source=see_link\">",
"    see \"Talc (sterile): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6021564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sclerosol&reg;;",
"     </li>",
"     <li>",
"      Sterile Talc Powder&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6021566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Sclerosing Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6021773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pleural effusion:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intrapleural aerosol: 4-8 g (1-2 cans) as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intrapleural instillation: 5 g",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F247656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, powder, intrapleural:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sclerosol&reg;: 4 g (4 g) [contains chlorofluorocarbon]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, intrapleural:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sterile Talc Powder&trade;: USP: 100% (5 g)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6021774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after adequate drainage of the effusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sclerosol&reg; Intrapleural Aerosol: Shake well and attach delivery tube. Insert delivery tube through pleural trocar, manually press on actuator button of canister to release; point in several different directions to distribute to all pleural surfaces. Keep canister in an upright position. Rate of delivery is 0.4 g per second.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sterile Talc Powder&trade;: Administer as a slurry. Shake well before instillation. Empty contents of each syringe into chest cavity through the chest tube by gently applying pressure to syringe plunger. After administration, flush with 10-25 mL of NS. Clamp chest tube and have patient rotate from supine to alternating decubitus positions at 20-30 minute intervals for 2 hours. For intrapleural use only;",
"     <b>",
"      not for I.V. administration.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F247657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of recurrence of malignant pleural effusion in symptomatic patients",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6021574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Asystolic arrest, chest pain, hypotension (transient), hypovolemia, MI, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fever (generally lasting &lt;24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Bleeding (localized), infection at administration site, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: ARDS, bronchopleural fistula, dyspnea, empyema, hemoptysis, hypoxemia, pneumonia, pulmonary edema, pulmonary embolism, subcutaneous emphysema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6021570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6021571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pulmonary effects: Acute pneumonitis and acute respiratory distress syndrome (including one death) have rarely been reported with higher doses (10 g).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sclerosol&reg;: Contents under pressure and should be kept away from any heat source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Should not be used to treat malignancies; does not have antineoplastic activity. Clinicians should evaluate need for future diagnostic procedures before use; sclerosis of pleural space may preclude subsequent procedures (eg, pneumonectomy for transplantation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6021567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6021568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women; use only if potential benefit outweighs possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol powder",
"     </b>",
"     (Sclerosol Intrapleural Intrapleural)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (30 g): $122.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Sterile Talc Powder Intrapleural)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (1): $97.50",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6021771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induces an inflammatory reaction that promotes adherence of the visceral to the parietal pleura, therefore, preventing reaccumulation of pleural fluid.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dresler CM, Olak J, Herndon JE, et al, &ldquo;Phase III Intergroup Study of Talc Poudrage Vs Talc Slurry Sclerosis for Malignant Pleural Effusion,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2005, 127(3):909-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28274/abstract-text/15764775/pubmed\" id=\"15764775\" target=\"_blank\">",
"        15764775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kvale PA, Seleecky PA, and Prakash UB, &ldquo;Palliative Care in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition),&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 132(3 Suppl):368-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28274/abstract-text/17873181/pubmed\" id=\"17873181\" target=\"_blank\">",
"        17873181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9496 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-8FC26C7E2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28274=[""].join("\n");
var outline_f27_39_28274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6021564\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6021566\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6021773\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247656\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6021774\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F247657\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6021574\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6021570\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6021571\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6021567\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6021568\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323637\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6021771\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9496|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/55/39795?source=related_link\">",
"      Talc (sterile): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_39_28275="Central L femoral anatomy";
var content_f27_39_28275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External landmarks for access to the femoral vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 577px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The midinguinal point lying half-way between the anterior superior iliac spine and the symphysis pubis marks the normal location of the femoral artery. The femoral vein lies just medial to the artery. Remember that pulsations will be felt in the femoral vein in cardiac arrest patients receiving chest compressions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28275=[""].join("\n");
var outline_f27_39_28275=null;
var title_f27_39_28276="Fomepizole: Pediatric drug information";
var content_f27_39_28276=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fomepizole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"    see \"Fomepizole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/14/22755?source=see_link\">",
"    see \"Fomepizole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F173900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Antizol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15125571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Antizol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Ethylene Glycol Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Methanol Toxicity",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"      see \"Fomepizole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adults",
"     <b>",
"      not requiring",
"     </b>",
"     hemodialysis: Initial: 15 mg/kg loading dose; followed by 10 mg/kg every 12 hours for 4 doses; then 15 mg/kg every 12 hours until ethylene glycol or methanol levels have been reduced to &lt;20 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adults",
"     <b>",
"      requiring",
"     </b>",
"     hemodialysis: Since fomepizole is dialyzable, follow the above dose recommendations at intervals related to institution of hemodialysis and its duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose at the beginning of hemodialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If &lt;6 hours since last fomepizole dose: Do",
"     <b>",
"      not",
"     </b>",
"     administer dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If &ge;6 hours since last fomepizole dose: Administer next scheduled dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose during hemodialysis: Administer every 4 hours or as continuous infusion 1-1.5 mg/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose at the time hemodialysis is completed (dependent upon the time between the last dose and the end of hemodialysis):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;1 hour: Do",
"     <b>",
"      not",
"     </b>",
"     administer at the end of hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 hours: Administer",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the next scheduled dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;3 hours: Administer the next scheduled dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose off hemodialysis: Give next scheduled dose 12 hours from last dose administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment",
"     </b>",
"     : Fomepizole is substantially excreted by the kidney and the risk of toxic reactions to this drug may be increased in patients with impaired renal function; no dosage recommendations for patients with impaired renal function have been established",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 1 g/mL (1.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antizol&reg;: 1 g/mL (1.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V. Dilute in at least 100 mL NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W (&lt;25 mg/mL); infuse over 30 minutes; rapid infusion of concentrations &ge;25 mg/mL has been associated with vein irritation and phlebosclerosis",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; fomepizole solidifies at temperatures &lt;25&deg;C (77&deg;F); if solidification occurs, liquefy by running the vial under warm water or by holding in the hand; solidification does not affect the efficacy, safety, or stability of fomepizole; stabile diluted in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W for 48 hours; does not contain a preservative; use within 24 hours of dilution",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidote for ethylene glycol (antifreeze) or methanol toxicity; may be useful in propylene glycol toxicity; FDA approved in ages &ge;18 years",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fomepizole may be confused with omeprazole",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F173925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, facial flush, hypotension, shock, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, dizziness, drowsiness increased, fever, headache, lightheadedness, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased, bad/metallic taste, diarrhea, heartburn, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, disseminated intravascular coagulation (DIC), eosinophilia, lymphangitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site reaction, injection site inflammation, pain during injection, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Backache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Nystagmus, transient blurred vision, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Anuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Abnormal smell, hiccups, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Multiorgan failure, speech disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Mild allergic reactions (mild rash, eosinophilia)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fomepizole, other pyrazoles, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of ethylene glycol ingestion may require treatment of metabolic acidosis, acute renal failure, adult respiratory distress syndrome, and hypocalcemia; dialysis should be considered, in addition to fomepizole therapy, in patients with acute renal failure, severe metabolic acidosis, or a serum ethylene glycol concentration &gt;50 mg/dL; adjust dosage for renal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     By inhibiting the action of alcohol dehydrogenase, fomepizole reduces the elimination of alcohol; this must be considered when using fomepizole, as alcohol is often ingested concomitantly by patients with ethylene glycol intoxication; likewise, alcohol may reduce the elimination of fomepizole by the same mechanism. Pediatric administration is not FDA approved; however, safe and efficacious use in this patient population for ethylene glycol and methanol intoxication has been reported (Baum, 2000; Benitez, 2000; Boyer, 2001; Brown, 2001; De Brabander, 2005; Detaille, 2004; Fisher, 1998).  Consider consultation with a clinical toxicologist or poison control center.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F173873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F173886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs, arterial blood gases, acid-base status, urinary oxalate, anion and osmolar gaps, clinical signs and symptoms of toxicity (arrhythmias, seizures, coma); serum and urinary ethylene glycol or serum methanol level depending upon the agent ingested; formic acid level (methanol ingestion)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1058827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethylene glycol or methanol serum concentration: Goal: &lt;20 mg/dL; therapeutic plasma fomepizole level: 0.8 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A competitive alcohol dehydrogenase inhibitor, fomepizole complexes and inactivates alcohol dehydrogenase thus preventing formation of the toxic metabolites of the alcohols",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.6-1.02 L/kg; rapidly distributes into total body water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Liver; primarily to 4-carboxypyrazole; after single doses, exhibits saturable, Michaelis-Menton kinetics; with multiple dosing, fomepizole induces its own metabolism via the cytochrome P450 system; after enzyme induction elimination follows first order kinetics",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 1% to 3.5% excreted unchanged in the urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1058833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If ethylene glycol poisoning is left untreated, the natural progression of the poisoning leads to accumulation of toxic metabolites, including glycolic and oxalic acids; these metabolites can induce metabolic acidosis, seizures, stupor, coma, calcium oxaluria, acute tubular necrosis and death; as ethylene glycol levels diminish in the blood when metabolized to glycolate, the diagnosis of this poisoning may be difficult",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baum CR, Langman CB, Oker EE, et al, &ldquo;Fomepizole Treatment of Ethylene Glycol Poisoning in an Infant,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(6):1489-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28276/abstract-text/11099610/pubmed\" id=\"11099610\" target=\"_blank\">",
"        11099610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benitez JG, Swanson-Biearman B, and Krenzelok EP, &ldquo;Nystagmus Secondary to Fomepizole Administration in a Pediatric Patient,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2000, 38(7):795-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28276/abstract-text/11192468/pubmed\" id=\"11192468\" target=\"_blank\">",
"        11192468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW, Mejia M, Woolf A, et al, &ldquo;Severe Ethylene Glycol Ingestion Treated Without Hemodialysis,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 107(1):172-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28276/abstract-text/11134452/pubmed\" id=\"11134452\" target=\"_blank\">",
"        11134452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown MJ, Shannon MW, Woolf A, et al, &ldquo;Childhood Methanol Ingestion Treated With Fomepizole and Hemodialysis,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(4):e77-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28276/abstract-text/11581485/pubmed\" id=\"11581485\" target=\"_blank\">",
"        11581485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Brabander N, Wojciechowski M, De Decker K, et al, &ldquo;Fomepizole as a Therapeutic Strategy in Paediatric Methanol Poisoning: A Case Report and Review of the Literature,&rdquo;",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2005, 164(3):158-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28276/abstract-text/15578220/pubmed\" id=\"15578220\" target=\"_blank\">",
"        15578220",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Detaille T, Wallemacq P, Clement de Clety S, et al, &ldquo;Fomepizole Alone for Severe Infant Ethylene Glycol Poisoning,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2004, 5(5):490-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28276/abstract-text/15329167/pubmed\" id=\"15329167\" target=\"_blank\">",
"        15329167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Druteika DP, Zed PJ, and Ensom MH, &ldquo;Role of Fomepizole in the Management of Ethylene Glycol Toxicity,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2002, 22(3):365-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28276/abstract-text/11899949/pubmed\" id=\"11899949\" target=\"_blank\">",
"        11899949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisher DM and Diaz JE, &ldquo;Pediatric Methanol Poisoning Treated With Fomepizole (Antizol&reg;),&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1998, 36:512.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13323 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28276=[""].join("\n");
var outline_f27_39_28276=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173900\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125571\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058824\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058818\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173877\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173863\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058829\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058821\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058828\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914140\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173925\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058832\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058817\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058816\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299362\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220494\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173873\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173886\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058823\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058827\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058815\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058831\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058833\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13323|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=related_link\">",
"      Fomepizole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/14/22755?source=related_link\">",
"      Fomepizole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_39_28277="Transhepatic biliary drain placement";
var content_f27_39_28277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Transhepatic biliary drain placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 717px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28277=[""].join("\n");
var outline_f27_39_28277=null;
var title_f27_39_28278="Intermittent BBB tutorial";
var content_f27_39_28278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Intermittent bundle branch block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 164px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    QRS complexes with a right bundle branch block morphology are interspersed with normal complexes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28278=[""].join("\n");
var outline_f27_39_28278=null;
var title_f27_39_28279="Blastomycosis chest CT and histopathology";
var content_f27_39_28279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Lung nodule caused by Blastomyces dermatitidis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blastomycosis.",
"    <br>",
"     (A) View of the right lower lobe from a computed tomography (CT) image (2.5-mm collimation) shows a triangular nodule in the right lower lobe.",
"     <br>",
"      (B) Dynamic CT scans obtained at a similar level to (A) demonstrate marked and persistent enhancement, suggesting an active inflammatory nodule.",
"      <br>",
"       (C) Photomicrograph of a wedge resection specimen demonstrates foci of granulomatous inflammation (arrows).",
"       <br>",
"        (D) Photomicrograph with Gomori methenamine silver staining reveals yeast forms of",
"        <em>",
"         Blastomyces dermatitidis",
"        </em>",
"        . The patient was a 69-year-old woman.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced with permission from: Imaging of Pulmonary Infections, M&uuml;ller NL, Franquet T, Lee KS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"        </div>",
"        <div class=\"contractual\">",
"         <br/>",
"         <a href=\"file://www.lww.com\">",
"          file://www.lww.com",
"         </a>",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28279=[""].join("\n");
var outline_f27_39_28279=null;
var title_f27_39_28280="Malignancy after hematopoietic cell transplantation";
var content_f27_39_28280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignancy after hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/39/28280/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/39/28280/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/39/28280/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/39/28280/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/39/28280/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/39/28280/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/39/28280/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of hematopoietic cell transplantation (HCT) has led to the unfortunate complication of secondary malignancies in patients who would otherwise be long-term survivors. Among the malignancies are solid tumors, acute leukemia, myelodysplastic syndromes, and post-transplant lymphoproliferative disease (PTLD). While the former occur late in the post-transplant course (&gt;3 years post transplant), PTLD usually occurs in the first year after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk for development of secondary malignancies following HCT will be reviewed here. Other complications of HCT and the development of secondary malignancies following solid organ transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=see_link\">",
"     \"The approach to hematopoietic cell transplantation survivorship\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL OBSERVATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy followed by hematopoietic cell transplantation (HCT) have an increased risk of developing myelodysplastic syndrome, acute leukemia, post-transplant lymphoproliferative disease, and solid tumors when compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/2-10\">",
"     2-10",
"    </a>",
"    ]. These cancers are expected to have a significant impact upon survival in this patient population. The relative risk of developing a malignancy following HCT has varied greatly among studies and is dependent upon a number of patient and treatment factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Radiation dose and fields",
"     </li>",
"     <li>",
"      Chemotherapy agents and doses administered",
"     </li>",
"     <li>",
"      Length and severity of immunodeficiency",
"     </li>",
"     <li>",
"      Chronic graft-versus-host disease",
"     </li>",
"     <li>",
"      Epstein-Barr virus infection",
"     </li>",
"     <li>",
"      Patient age at treatment",
"     </li>",
"     <li>",
"      Smoking history",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these factors, certain patients may have a genetic predisposition towards developing second malignancies after HCT. As an example, patients transplanted for Fanconi anemia or primary immunodeficiency diseases have an inborn susceptibility to cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H12#H12\">",
"     \"Inherited aplastic anemia in children\", section on 'Long-term complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15631842\">",
"    <span class=\"h2\">",
"     Solid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid tumors are relatively uncommon among transplant survivors, but occur much more frequently in this population when compared with the general population (ie, high relative risk). Large retrospective series have estimated the cumulative incidence rates of secondary solid tumors at 1 to 2 percent at 10 years and 3 to 5 percent at 20 years after allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Smaller retrospective studies of autologous HCT have estimated the cumulative incidence rates of secondary solid tumors at 4 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Solid tumors of practically every type have been described in the allogeneic and autologous HCT setting.",
"   </p>",
"   <p>",
"    The largest experience comes from a review of 28,874 allogeneic transplant recipients by the International Bone Marrow Transplant Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Patients transplanted for Fanconi anemia or primary immunodeficiency diseases were excluded because of their genetic susceptibility to cancer. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HCT survivors developed new solid cancers at twice the expected rate in the general population (observed-to-expected ratio 2.1; 95% CI 1.8-2.5). The cumulative incidence of new solid cancers was 1 percent at 10 years, 2.2 percent at 15 years, and 3.3 percent at 20 years after transplantation.",
"     </li>",
"     <li>",
"      The observed-to-expected ratio increased with time since transplantation.",
"     </li>",
"     <li>",
"      The risk was significantly increased for malignant melanoma and cancers of the buccal cavity, liver, brain or other parts of the central nervous system, thyroid, bone, and connective tissue.",
"     </li>",
"     <li>",
"      Predisposing factors included younger age, higher doses of radiation therapy, and, for squamous cell cancers of the buccal cavity, chronic graft-versus-host disease.",
"     </li>",
"     <li>",
"      For those irradiated at ages under 30 years, the risk of developing a non-squamous cell carcinoma following conditioning radiation was nine times that of nonirradiated patients. The comparable risk for older patients was 1.1.",
"     </li>",
"     <li>",
"      Among patients under the age of 30, a significant excess risk of cancer was noted in patients transplanted for acute myeloid leukemia (excess risk 26.6 per 10,000 patients per year), acute lymphoblastic leukemia (17.5 per 10,000 patients per year), and chronic myeloid leukemia (9.7 per 10,000 patients per year). Among patients over the age of 30, a significant excess risk was noted only in those transplanted for acute myeloid leukemia (21 per 10,000 patients per year). (See",
"      <a class=\"local\" href=\"#H25091611\">",
"       'Risk according to reason for HCT'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There was no significant increase in risk among patients transplanted for nonmalignant hematologic diseases other than aplastic anemia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'HCT for nonmalignant hematologic disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were noted in a report of 1036 consecutive patients who were transplanted because of malignancy, severe aplastic anemia, and inborn errors of the hematopoietic and immune systems [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/8\">",
"     8",
"    </a>",
"    ]. The transplants were performed after 1985 and all analyzed patients survived for at least five years. At a median follow-up of 10.7 years, the actuarial incidence of second malignancy was 3.5 percent at 10 years and 12.8 percent at 15 years; the risk was 3.8 times higher than that in an age-matched control population. The most frequent sites of the 53 tumors were the skin (14 patients), oral cavity (seven), uterus or cervix (five), thyroid (five), breast (four), and glial tissue (three). The two major risk factors were older age and the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to prevent chronic graft-versus-host disease.",
"   </p>",
"   <p>",
"    The largest autologous experiences comes from a multicenter retrospective analysis that evaluated the incidence of secondary solid tumors in 1347 patients with lymphoma treated with high dose sequential chemotherapy followed by autologous HCT rescue between 1985 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/10\">",
"     10",
"    </a>",
"    ]. At a median follow-up of seven years, the estimated five-, 10- and 15-year cumulative incidences of solid tumors were 2.54, 6.79, and 9.14 percent, respectively. Of the 65 secondary solid tumors identified, the most common were in the lung, gastrointestinal tract, skin, breast, head and neck, bladder, and thyroid. The risk of developing a secondary solid tumor was increased in patients age &gt;45, in those receiving radiation after high dose sequential chemotherapy (hazard ratio 0.89, 95% CI 0.64-1.25), and in patients whose treatment included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (hazard ratio 0.59, 95% CI 0.47-0.74). Despite the association with an increased risk of developing secondary solid tumors, the addition of rituximab to the treatment program resulted in improved overall survival rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1273797\">",
"    <span class=\"h3\">",
"     Nonmelanoma skin cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCT survivors are at increased risk of developing nonmelanoma skin cancer. Risk factors include radiation exposure and graft-versus-host disease. A report evaluated the incidence of, and risk factors for, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in 4810 patients who received allogeneic HCT and survived &gt;100 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/12\">",
"     12",
"    </a>",
"    ]. Twenty-year cumulative incidences of BCC and SCC were 6.5 and 3.4 percent, respectively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factors significantly influencing development of BCC included total body irradiation, especially for those &lt;18 years of age at the time of HCT, light-skinned patients, and chronic GVHD.",
"     </li>",
"     <li>",
"      Factors significantly influencing development of SCC included both acute and chronic GVHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All HCT survivors should be encouraged to avoid unnecessary sun exposure and to perform regular self skin examinations. Physicians caring for transplant patients should be aware of these risks and perform appropriate screening examinations. The diagnosis of nonmelanoma skin cancer is presented separately. (See",
"    <a class=\"local\" href=\"#H1273635\">",
"     'Screening and preventative measures'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1273804\">",
"    <span class=\"h3\">",
"     Squamous cell cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCT survivors are at increased risk for the development of squamous cell cancers (SCC) of the skin and oral cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. The risk of SCC is particularly high among patients with chronic graft-versus-host disease (GVHD), prior chronic lichenoid lesions of the oral mucosa,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of Fanconi&rsquo;s anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/5,7,14\">",
"     5,7,14",
"    </a>",
"    ]. SCC of the oral cavity can involve the buccal mucosa, salivary glands, gingiva, lip, or tongue. The diagnosis should be suspected in patients with nonhealing oral lesions, leukoplakia, localized oral pain, or changes in the mucosal color or texture. SCC in this setting is often clinically aggressive and screening is recommended. (See",
"    <a class=\"local\" href=\"#H1273635\">",
"     'Screening and preventative measures'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of oral SCCs arising in long-term survivors of allogeneic HCT, the source of the malignant cells was surprisingly found to be the HCT donor in four of the eight cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/15\">",
"     15",
"    </a>",
"    ]. Of interest, none of these four hosts had personal risk factors for oral SCC (eg, smoking, alcohol abuse); all had a previous history of extensive chronic GVHD with oral mucosa involvement, requiring prolonged immunosuppressive therapy.",
"   </p>",
"   <p>",
"    The relationship between SCC and GVHD was further explored in a study encompassing an international cohort of over 24,000 patients who underwent allogeneic or syngeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/14\">",
"     14",
"    </a>",
"    ]. The predominant underlying primary diseases for patients in whom SCC developed were leukemia and severe aplastic anemia, with a median time from HCT to the diagnosis of a solid tumor of 7.0 years (range: 0.9 to 23 years), and a cumulative incidence of 1.1 percent at 20 years. Risk factors significantly associated with development of SCC included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe chronic GVHD &mdash; Relative risk (RR) 9.9",
"     </li>",
"     <li>",
"      Severe chronic GVHD treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      &mdash; RR 16.2",
"     </li>",
"     <li>",
"      Severe chronic GVHD treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      for &ge;24 months &mdash; RR 28.8",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is now rarely, if ever, used for the treatment of chronic GVHD, this complication may be less of a problem for current and future patients. Until a decreased incidence is realized, serial oral examinations are indicated for all transplant survivors. (See",
"    <a class=\"local\" href=\"#H1273635\">",
"     'Screening and preventative measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265551523\">",
"    <span class=\"h3\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major risk factors for breast cancer in this population are younger age at HCT, exposure of the breast tissue to radiotherapy, and disruption of ovarian function by alkylating agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other chemotherapy.",
"   </p>",
"   <p>",
"    In a multicenter study of 3337 female survivors of allogeneic HCT, 52 developed breast cancer (1.6 percent) at a median of 12.5 years post-transplant, with a 25-year cumulative incidence of 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/16\">",
"     16",
"    </a>",
"    ]. The risk of developing breast cancer was significantly higher for those who received total body irradiation (hazard ratio 4.0) and those who were younger at the time of HCT (hazard ratio 9.5 for HCT at &lt;18 years of age).",
"   </p>",
"   <p>",
"    Female HCT survivors should be counseled about the need for regular breast cancer screening. (See",
"    <a class=\"local\" href=\"#H1273635\">",
"     'Screening and preventative measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265549621\">",
"    <span class=\"h2\">",
"     Secondary myelodysplasia/acute leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCT survivors are at increased risk of developing acute leukemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myelodysplastic syndrome (MDS) when compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/10,17\">",
"     10,17",
"    </a>",
"    ]. Risk factors include the use of cytotoxic chemotherapy (eg, alkylating agents)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ionizing radiation therapy given as large fields that include the bone marrow. In addition, there are emerging data regarding donor-derived leukemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myelodysplastic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/18-23\">",
"     18-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter retrospective analysis evaluated the incidence of secondary",
"    <span class=\"nowrap\">",
"     MDS/acute",
"    </span>",
"    leukemia in 1347 patients with lymphoma treated with high dose sequential chemotherapy followed by autologous HCT rescue between 1985 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/10\">",
"     10",
"    </a>",
"    ]. At a median follow-up of seven years, the estimated five-, 10- and 15-year cumulative incidences of",
"    <span class=\"nowrap\">",
"     MDS/acute",
"    </span>",
"    leukemia were 3.1, 4.5, and 6.8 percent, respectively. The most secondary acute leukemias were most commonly of myeloid lineage, but there were two cases of acute lymphoblastic leukemia. The risk of developing secondary",
"    <span class=\"nowrap\">",
"     MDS/acute",
"    </span>",
"    leukemia was higher among males (hazard ratio 3.1, 95% CI 1.52-6.28) and those who were infused with peripheral blood progenitor cells collected during a second harvest (hazard ratio 2.2, 95% CI 1.3-4.0).",
"   </p>",
"   <p>",
"    Secondary",
"    <span class=\"nowrap\">",
"     MDS/acute",
"    </span>",
"    leukemia should be suspected in patients who develop unexplained anemia, neutropenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia. The diagnosis, treatment, and prognosis of therapy-associated AML are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15631895\">",
"    <span class=\"h2\">",
"     Post-transplant lymphoproliferative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-transplant lymphoproliferative disease (PTLD) occurs after solid organ and hematopoietic cell transplantation and is importantly related to the presence of Epstein-Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/24\">",
"     24",
"    </a>",
"    ]. The cumulative incidence is 1 percent at 10 years, with 82 percent occurring in the first year. The risk of developing PTLD is highest at one to five months post-transplant followed by a steep decline in incidence after one year (120 versus 5 cases per 10,000 patients per year among survivors for more than one year). The risk of developing PTLD varies and is dependent upon features of the donor, recipient, and preparative regimen in particular with the use of T cell depletion. This topic is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25091611\">",
"    <span class=\"h1\">",
"     RISK ACCORDING TO REASON FOR HCT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     HCT for aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of secondary malignancy is especially high in patients who undergo transplantation for severe aplastic anemia (SAA), which can be either acquired or congenital (Fanconi anemia). It is difficult to evaluate the role of HCT in the development of secondary malignancies in SAA because malignancy also occurs after use of immunosuppressive therapy alone in SAA, which often consists of antithymocyte globulin, corticosteroids, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=see_link\">",
"     \"Aplastic anemia: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest experience with malignancy in patients with SAA comes from the European Bone Marrow Transplantation Group and included 748 patients who underwent HCT and 860 treated with immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/25\">",
"     25",
"    </a>",
"    ]. Hematologic malignancies occurring within six months or solid tumors developing within 12 months were excluded since they might have been due to the underlying disease rather than therapy. The 10-year cumulative risk of second malignancies was 3.1 percent with HCT and 18.8 percent with immunosuppressive therapy. The distribution of tumors was different: primarily solid tumors after HCT and primarily hematologic malignancies (acute leukemia and myelodysplastic syndrome) after immunosuppressive therapy. The risk of solid tumors was the same in the two groups. The major risk factors for malignancy after HCT were increasing age and the use of radiation therapy in the conditioning regimen.",
"   </p>",
"   <p>",
"    In a second series, 700 patients with either SAA or Fanconi anemia underwent allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/26\">",
"     26",
"    </a>",
"    ]. The actuarial risk of developing a secondary malignancy at 20 years was 14 percent overall but was 42 percent in the 79 patients with Fanconi anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/26\">",
"     26",
"    </a>",
"    ]. Among the tumors, there were 18 solid tumors (all but one squamous cell carcinoma) presenting at a median of 99 months after transplant and five hematologic malignancies (acute lymphoblastic leukemia and post-transplant lymphoproliferative disease) presenting at a median of three months post-transplant. Among the patients with SAA, the major risk factors for malignancy were the use of irradiation as part of the conditioning regimen and of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for chronic graft-versus-host disease. Since neither of these modalities is commonly used at present, it is likely that the current risk of secondary malignancy is lower. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link\">",
"     \"Hematopoietic cell transplantation in aplastic anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     HCT for malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second malignancies, both hematologic and non-hematologic, have been observed following HCT for a variety of malignant conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/27\">",
"     27",
"    </a>",
"    ]. Among patients with non-Hodgkin lymphoma or Hodgkin lymphoma, autologous bone marrow or peripheral blood progenitor cell transplantation is associated with an estimated risk of second cancers, primarily myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), of 8 to 21 percent at 5 to 10 years, and as high as 29 percent at 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/28-33\">",
"     28-33",
"    </a>",
"    ]. Among patients with Hodgkin lymphoma, solid tumors occur with increased frequency (relative risk 5.2) compared with matched nontransplanted controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A central question is whether the increased risk of secondary MDS and leukemia is due to the chemotherapy and radiation therapy used during the transplant procedure or to the cumulative effect of all of the therapy that the patient has received [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/34\">",
"     34",
"    </a>",
"    ]. A number of observations are compatible with a primary role for prior therapy in causing marrow damage leading to secondary",
"    <span class=\"nowrap\">",
"     MDS/AML,",
"    </span>",
"    rather than the transplant procedure itself [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/31,35-37\">",
"     31,35-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of patients with Hodgkin lymphoma, the incidence of MDS and AML was similar in transplanted and matched nontransplanted patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients have cytogenetic abnormalities prior to HCT and are at particularly high risk for subsequent development of MDS or acute leukemia. In one report of seven such patients with Hodgkin lymphoma, MDS or acute leukemia occurred in all three who were transplanted, compared with an expected incidence of 9 to 18 percent in all transplants [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/35\">",
"       35",
"      </a>",
"      ]. Every effort should be made to identify these patients prior to autologous HCT with screening bone marrow aspiration, biopsy, and cytogenetic studies. If a cytogenetic abnormality is found, altering the treatment approach to an allogeneic HCT is indicated.",
"     </li>",
"     <li>",
"      A third study evaluated 188 patients with multiple myeloma who underwent autologous transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/36\">",
"       36",
"      </a>",
"      ]. The patients were divided into two groups: one exposed to prolonged therapy with alkylating agents prior to transplantation and one exposed to only one cycle of chemotherapy prior to transplantation. All seven patients who developed MDS, which occurred at a median of 24 months, were in the group with high pre-transplant exposure to chemotherapeutic agents. Due to these and other findings, it is recommended to avoid alkylating agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      for the treatment of transplant-eligible multiple myeloma patients prior to collection of hematopoietic stem cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link&amp;anchor=H2#H2\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Initial chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A somewhat different conclusion was reached in a report that evaluated 612 patients who received autologous HCT for Hodgkin lymphoma or non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/38\">",
"     38",
"    </a>",
"    ]. The estimated cumulative probability of therapy-related",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    was 8.6 percent at six years. The relative risk of this complication was 7.7 in patients who received stem cell priming with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    . Multivariate analysis revealed an association with pre-transplant radiation but not pre-transplant chemotherapy or the conditioning regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HCT for nonmalignant hematologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary malignancies have been described after allogeneic transplantation for nonmalignant hematologic diseases other than severe aplastic anemia and Fanconi anemia, such as hemoglobinopathies (eg, beta thalassemia) and inborn errors of metabolism. It is unclear, however, if the risk is increased. Data from the International Bone Marrow Transplant Registry suggested that patients undergoing HCT for nonmalignant diseases had an incidence of secondary malignancies that was not significantly increased when compared with the expected value in the normal population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, although malignancy occurs after HCT for beta thalassemia, the rate does not appear to be higher than that seen in patients with this disorder who are not transplanted. In the Registry report described above, patients with congenital immune deficiencies were excluded because they may have an underlying increase in the risk for cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=see_link&amp;anchor=H15#H15\">",
"     \"Long-term management of the thalassemic patient after hematopoietic cell transplantation\", section on 'Secondary malignancies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1273635\">",
"    <span class=\"h1\">",
"     SCREENING AND PREVENTATIVE MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;While HCT survivors are at increased risk of developing secondary malignancies, the ideal screening program has not been defined. No prospective analyses have evaluated the benefit of screening in this population. However, extrapolation of data from other settings suggests that the ability to prevent and detect solid organ malignancies in the HCT survivor relies upon periodic screening examinations and strict adherence to prophylactic measures. Our approach is similar to that proposed in the joint screening recommendations provided by the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk awareness counseling annually &mdash; HCT survivors should be advised of their increased risk of developing a malignancy following HCT and encouraged to report any concerning symptoms to their physician. Smoking cessation should be recommended and patients should be counseled to limit unprotected sun exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening clinical assessment annually &mdash; In addition to a routine physical examination, HCT survivors should undergo an at least annual complete skin examination and dental evaluation to monitor for the development of skin and oral cancers, respectively. More frequent oral examination (eg, every six months) should be considered for patients with chronic GVHD, prior chronic lichenoid lesions of the oral mucosa,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a history of Fanconi&rsquo;s anemia. &nbsp;",
"     </li>",
"     <li>",
"      HCT survivors should be encouraged to participate in routine age-appropriate cancer surveillance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of preventive medicine in adults\", section on 'Cancer morbidity and mortality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Female HCT survivors should undergo screening for breast cancer beginning no later than age 40 years. For patients who have received total body or chest irradiation, breast cancer screening should begin eight years after radiation or at age 25 years, whichever occurs later.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ideal test to use for breast cancer screening has not been determined and clinical practice varies. The international working group that proposed the guidelines described above suggest the use of mammography alone. In contrast, the American Cancer Society suggests the use of mammography for most patients, but also proposes that woman who received radiation to the chest between the age of 10 and 35 years undergo screening with both annual breast magnetic resonance imaging (MRI) and mammography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28280/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=see_link&amp;anchor=H1167672651#H1167672651\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Routine testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5642651\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiotherapy followed by hematopoietic cell transplantation (HCT) have an increased risk of developing myelodysplastic syndrome (MDS), acute leukemia, post-transplant lymphoproliferative disease (PTLD), and solid tumors when compared with the general population. These secondary malignancies are expected to have a significant impact upon survival in this patient population. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General observations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCT survivors develop new solid cancers at approximately twice the expected rate in the general population. Retrospective series have estimated the cumulative incidence rates at 1 to 2 percent at 10 years and 3 to 5 percent at 20 years after allogeneic HCT and at 4 percent 10 years following autologous HCT. Solid tumors of practically every type have been described in the allogeneic and autologous HCT setting. (See",
"      <a class=\"local\" href=\"#H15631842\">",
"       'Solid tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiation exposure and graft-versus host disease (GVHD) place HCT survivors at increased risk of developing nonmelanoma skin cancer. All HCT survivors should be encouraged to avoid unnecessary sun exposure and to perform regular self skin examinations. (See",
"      <a class=\"local\" href=\"#H1273797\">",
"       'Nonmelanoma skin cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1273635\">",
"       'Screening and preventative measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Squamous cell cancers (SCC) of the oral cavity are more common in HCT survivors, especially among those with chronic GVHD, prior chronic lichenoid lesions of the oral mucosa,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a history of Fanconi&rsquo;s anemia. The diagnosis should be suspected in patients with nonhealing oral lesions, leukoplakia, localized oral pain, or changes in the mucosal color or texture. Oral screening should be performed at least annually in all HCT survivors. (See",
"      <a class=\"local\" href=\"#H1273804\">",
"       'Squamous cell cancers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1273635\">",
"       'Screening and preventative measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three major risk factors for breast cancer in this population are younger age at HCT, exposure of the breast tissue to radiotherapy, and disruption of ovarian function by alkylating agents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other chemotherapy. Female HCT survivors should undergo screening for breast cancer beginning no later than age 40 years. For patients who have received total body or chest irradiation, breast cancer screening should begin eight years after radiation or at age 25 years, whichever occurs later. (See",
"      <a class=\"local\" href=\"#H265551523\">",
"       'Breast cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1273635\">",
"       'Screening and preventative measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCT survivors are at increased risk of developing acute leukemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      MDS when compared with the general population. Risk factors include the use of cytotoxic chemotherapy (eg, alkylating agents)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      total body irradiation. (See",
"      <a class=\"local\" href=\"#H265549621\">",
"       'Secondary myelodysplasia/acute leukemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PTLD is a rare complication of HCT that is related to the presence of Epstein-Barr virus and typically occurs within the first year post-HCT. The risk of developing PTLD varies and is dependent upon features of the donor, recipient, graft manipulation, and preparative regimen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link&amp;anchor=H16930159#H16930159\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of secondary malignancy is increased among patients undergoing HCT for malignancy and is especially high in patients who undergo HCT for severe aplastic anemia. In contrast, the risk of malignancy after HCT does not appear to be increased among patients undergoing HCT for nonmalignant diseases other than severe aplastic anemia. (See",
"      <a class=\"local\" href=\"#H25091611\">",
"       'Risk according to reason for HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCT survivors should be advised of their risk of developing a malignancy following HCT and encouraged to report any concerning symptoms to their physician. In addition to routine age-appropriate cancer surveillance, increased surveillance for oral and breast cancers is indicated. (See",
"      <a class=\"local\" href=\"#H1273635\">",
"       'Screening and preventative measures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/1\">",
"      Lowe T, Bhatia S, Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/2\">",
"      Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/3\">",
"      Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/4\">",
"      Gallagher G, Forrest DL. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 2007; 109:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/5\">",
"      Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011; 117:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/6\">",
"      Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/7\">",
"      Rizzo JD, Curtis RE, Soci&eacute; G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/8\">",
"      Kolb HJ, Soci&eacute; G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/9\">",
"      Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol 2007; 25:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/10\">",
"      Tarella C, Passera R, Magni M, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011; 29:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/11\">",
"      Forrest DL, Nevill TJ, Naiman SC, et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplant 2003; 32:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/12\">",
"      Leisenring W, Friedman DL, Flowers ME, et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/13\">",
"      Lishner M, Patterson B, Kandel R, et al. Cutaneous and mucosal neoplasms in bone marrow transplant recipients. Cancer 1990; 65:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/14\">",
"      Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105:3802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/15\">",
"      Janin A, Murata H, Leboeuf C, et al. Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood 2009; 113:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/16\">",
"      Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 2008; 111:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/17\">",
"      Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003; 101:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/18\">",
"      Gustafsson B, Moell J, Leblanc K, et al. Donor cell-derived acute myeloid leukemia after second allogenic cord blood transplantation in a patient with Fanconi anemia. Pediatr Transplant 2012; 16:E241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/19\">",
"      Yamazaki R, Nakasone H, Wada H, et al. Recurrence of monoclonal gammopathy associated with donor-derived myelodysplastic syndrome after cord blood stem cell transplantation. Exp Hematol 2011; 39:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/20\">",
"      Alp&aacute;r D. Recurrent disease or donor cell leukemia?: Brain teaser after allogeneic bone marrow transplantation. Chimerism 2011; 2:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/21\">",
"      Nakamizo A, Akagi Y, Amano T, et al. Donor-derived adult T-cell leukaemia. Lancet 2011; 377:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/22\">",
"      Sala Torra O, Loeb KR. Donor cell-derived leukemia and myelodysplastic neoplasm: unique forms of leukemia. Am J Clin Pathol 2011; 135:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/23\">",
"      Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant 2011; 17:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/24\">",
"      Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol 2002; 118:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/25\">",
"      Soci&eacute; G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 1993; 329:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/26\">",
"      Deeg HJ, Soci&eacute; G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/27\">",
"      Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000; 95:3273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/28\">",
"      Miller JS, Arthur DC, Litz CE, et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994; 83:3780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/29\">",
"      Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/30\">",
"      Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87:3633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/31\">",
"      Andr&eacute; M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/32\">",
"      Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/33\">",
"      Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/34\">",
"      Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/35\">",
"      Chao NJ, Nademanee AP, Long GD, et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol 1991; 9:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/36\">",
"      Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/37\">",
"      Kalaycio M, Rybicki L, Pohlman B, et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006; 24:3604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/38\">",
"      Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/39\">",
"      Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/40\">",
"      Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28280/abstract/41\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3558 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28280=[""].join("\n");
var outline_f27_39_28280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5642651\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL OBSERVATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15631842\">",
"      Solid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1273797\">",
"      - Nonmelanoma skin cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1273804\">",
"      - Squamous cell cancers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265551523\">",
"      - Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265549621\">",
"      Secondary myelodysplasia/acute leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15631895\">",
"      Post-transplant lymphoproliferative disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25091611\">",
"      RISK ACCORDING TO REASON FOR HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HCT for aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HCT for malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HCT for nonmalignant hematologic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1273635\">",
"      SCREENING AND PREVENTATIVE MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5642651\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=related_link\">",
"      Aplastic anemia: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=related_link\">",
"      Hematopoietic cell transplantation in aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=related_link\">",
"      Long-term follow-up of the patient with classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=related_link\">",
"      Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35530?source=related_link\">",
"      The approach to hematopoietic cell transplantation survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_39_28281="Indinavir: Pediatric drug information";
var content_f27_39_28281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indinavir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"    see \"Indinavir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/28/3525?source=see_link\">",
"    see \"Indinavir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Crixivan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Crixivan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Protease Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"      see \"Indinavir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (use in combination with other antiretroviral agents):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Not approved for use; optimal dose not established; clinical trials in children 4-15 years of age used doses of 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 8 hours; maximum dose: 800 mg/dose every 8 hours; this dose produced AUCs and peak concentrations slightly higher than those seen in adults receiving the standard dose; however, in 50% of children studied, trough indinavir levels were lower than those observed in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults: 800 mg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ritonavir-boosted regimens:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Indinavir 400 mg twice daily with ritonavir 400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Indinavir 800 mg twice daily with ritonavir 100-200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Concomitant therapy with delavirdine, itraconazole, or ketoconazole:",
"     </b>",
"     Reduce dose of indinavir to 600 mg every 8 hours when used in combination with delavirdine 400 mg 3 times/day, itraconazole 200 mg twice daily or ketoconazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Concomitant therapy with efavirenz or nevirapine:",
"     </b>",
"     Increase dose of indinavir to 1000 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Concomitant therapy with lopinavir and ritonavir (Kaletra&reg;):",
"     </b>",
"     Reduce dose of indinavir to 600 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Concomitant therapy with nelfinavir:",
"     </b>",
"     Increase dose of indinavir to 1200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Concomitant therapy with rifabutin:",
"     </b>",
"     Increase dose of indinavir to 1000 mg every 8 hours and reduce dose of rifabutin to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the standard dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: No dosing information is available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild to moderate hepatic impairment: Decrease dose from 800 mg every 8 hours to 600 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe hepatic impairment: No dosing information is available",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Crixivan&reg;: 200 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with water on an empty stomach or with a light snack 1 hour before or 2 hours after a meal; may administer with other liquids (ie, skim milk, coffee, tea, juice) or a light snack (ie, dry toast with jelly or cornflakes with skim milk); do not administer with grapefruit juice. May administer with food if taken in combination with ritonavir (ie, meal restrictions are not required). If coadministered with didanosine, give at least 1 hour apart on an empty stomach. Administer every 8 hours around-the-clock to avoid significant fluctuation in serum levels.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store capsules at room temperature in original container with desiccant (capsules are sensitive to moisture)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents; (",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended); postexposure chemoprophylaxis following occupational exposure to HIV",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Indinavir may be confused with Denavir&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F182579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, fever, headache, malaise, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, acid reflux, anorexia, appetite increased, diarrhea, dyspepsia, nausea, serum amylase increased, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (dose dependent), jaundice, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: Dysuria, nephrolithiasis/urolithiasis, including flank pain with/without hematuria (dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal distention, acute renal failure, alopecia, anaphylactoid reactions, angina, arthralgia, bleeding (spontaneous in patients with hemophilia A or B), cerebrovascular disorder, cholesterol increased, crystalluria, depression, dry skin, erythema multiforme, fat redistribution, hemolytic anemia, hepatic failure, hepatitis, hydronephrosis, hyperpigmentation, immune reconstitution syndrome, interstitial nephritis (with medullary calcification and cortical atrophy), leukocyturia (severe and asymptomatic), MI, new-onset diabetes, pancreatitis, paresthesia (oral), paronychia, pharyngitis, pyelonephritis, QT prolongation, renal insufficiency, renal failure, Stevens-Johnson syndrome, torsade de pointes, triglycerides increased, upper respiratory infection, urticaria, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to indinavir or any component; concurrent therapy with amiodarone, cisapride, dihydroergotamine, ergonovine, ergotamine, methylergonovine, midazolam, pimozide, triazolam",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment; modify dose in patients with impaired liver function. Use of indinavir in HIV-infected pregnant patients is",
"     <b>",
"      not",
"     </b>",
"     recommended; significantly lower serum concentrations were observed in these patients receiving standard adult doses; optimal dose is not currently known. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Indinavir is a CYP3A4 isoenzyme inhibitor that interacts with numerous drugs. Due to potential serious and/or life-threatening drug interactions, some drugs are contraindicated. Concurrent use with atazanavir, rifampin, St John's wort, or certain cholesterol-lowering agents (lovastatin, simvastatin) is",
"     <b>",
"      not",
"     </b>",
"     recommended. Alteration of dose or serum concentration monitoring may be required with other medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Cases of nephrolithiasis, urolithiasis (children: 29%; adults: 12.4%), and nephrolithiasis associated with renal insufficiency, acute renal failure, or pyelonephritis with or without bacteremia have been reported. In pediatric patients, sterile leukocyturia (with possible elevations in serum creatinine) has been reported without clinical symptoms of nephrolithiasis. Maintain adequate hydration in all patients to minimize risk. If signs and symptoms of nephrolithiasis occur (flank pain with or without hematuria or microscopic hematuria), temporarily interrupt or discontinue therapy. Tubulointerstitial nephritis with medullary calcification and cortical atrophy has been reported in patients with asymptomatic severe leukocyturia; consider discontinuation of indinavir in patients with severe leukocyturia. Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents, including indinavir; this syndrome may require further patient assessment and therapy. Hepatitis, including hepatic failure and death, has been reported (causal relationship not established). Spontaneous bleeding episodes have been reported in patients with hemophilia A and B. New onset diabetes mellitus, exacerbation of diabetes and hyperglycemia have been reported in HIV-infected patients receiving protease inhibitors. Acute hemolytic anemia has been reported. Indirect hyperbilirubinemia (incidence: ~14%) and elevated serum transaminases may occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F182568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Indinavir may increase the serum concentration of ALPRAZolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May enhance the adverse/toxic effect of Indinavir. Indinavir may enhance the adverse/toxic effect of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: May decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Indinavir. Indinavir may increase the serum concentration of Bosentan. Management: Initiate bosentan at, or adjust bosentan to, 62.5 mg once daily or every other day (based on tolerability) in indinavir-treated patients (see ritonavir for dosing if that agent is used). Additionally, monitor for possible reduced response to indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Indinavir. Management: Indinavir should be administered on an empty stomach at least 1 hour apart from administration of buffer-containing formulations of didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Indinavir. Management: The appropriate dose adjustments for indinavir when used together with efavirenz are unknown. The use of higher unboosted indinavir doses is not likely an adequate approach.  Use of a ritonavir-boosted indinavir regimen could be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir, saquinavir, and lopinavir (with low-dose ritonavir). Management: Low-dose ritonavir boosting must be used when any protease inhibitor is used with etravirine.  Avoid use of etravirine in combination with atazanavir, fosamprenavir, full-dose ritonavir (600 mg twice daily), or tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Indinavir may increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Indinavir.  Management: Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with itraconazole.  Monitor for increased systemic effects (including adverse/toxic effects) of itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Indinavir may increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Indinavir.  Management: Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with ketoconazole.  Monitor for increased systemic effects (including adverse/toxic effects) of ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Indinavir. Management: Increased indinavir doses may be needed when used with nevirapine; however, specific dosing guidelines have not been established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Indinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Indinavir may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Indinavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Venlafaxine: May decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased absorption when administered with food high in calories, protein, or fat; 27% decrease in AUC when administered with grapefruit juice",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F182520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Placental passage in humans is minimal. No increased risk of overall birth defects has been observed according to data collected by the antiretroviral pregnancy registry. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk. Hyperbilirubinemia may occur in neonates following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to indinavir. Until optimal dosing during pregnancy has been established, the manufacturer does not recommend indinavir use in pregnant patients. The DHHS Perinatal HIV Guidelines consider indinavir an agent to be used in special circumstances when preferred and alternative agents cannot be used; however, if needed, indinavir must be used in combination with low-dose ritonavir during pregnancy (with ritonavir boosting, 82% of pregnant women reached target trough concentrations).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum bilirubin, cholesterol, triglycerides, amylase, lipase, liver function tests, urinalysis, blood glucose levels, CD4 cell count, plasma levels of HIV RNA, CBC",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A protease inhibitor which acts on an enzyme late in the HIV replication process after the virus has entered into the cell's nucleus preventing cleavage of the gag-pol protein precursors resulting in the production of immature, noninfectious virions; cross-resistance with other protease inhibitors is possible",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid (in the fasted state); presence of food high in calories, fat, and protein significantly decreases the extent of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver by CYP3A4 to inactive metabolites; 6 oxidative and 1 glucuronide conjugate metabolites have been identified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Wide interpatient variability in children: 15% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-17 years (n=18): 1.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1.8 &plusmn; 0.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with mild to moderate hepatic dysfunction: 2.8 &plusmn; 0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 0.8 &plusmn; 0.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 83% in feces as unabsorbed drug and metabolites; &sim;10% excreted in urine as unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/28/3525?source=see_link\">",
"      see \"Indinavir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Indinavir is not a cure for HIV. Some medicines should not be taken with indinavir; report the use of other medications, nonprescription medications, and herbal or natural products to your healthcare provider. Avoid the herbal medicine St John's wort and grapefruit juice. Indinavir may cause kidney stones; drink plenty of fluids to decrease the risk of kidney stone formation; adults should drink at least 48 ounces of liquids per day. Take indinavir every day as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do not double the next dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F6052683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One study in children 4-17 years of age (n=18), adjusted the indinavir dose and dosing interval to maintain trough plasma concentrations. A mean daily dose of 2043 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     was required with 9 of 18 children requiring doses every 6 hours (Fletcher, 2000). Other pediatric studies have also suggested that every 6 hour dosing may be needed in some children (Gatti, 2000) and that a wide range of doses (1250-2450 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) may be required (van Rossum, 2000a). However, it should be noted that the higher incidence of renal toxicity observed in children versus adults, may preclude studying higher doses of indinavir.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Two small studies assessed the use of indinavir in combination with ritonavir. One study used doses of indinavir 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily (n=4; 1-10 years of age); one patient attained high concentrations of both drugs and developed renal toxicity (van Rossum, 2000). Another study used doses of indinavir 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily in children (n=14); AUC and trough concentrations were similar to adults receiving ritonavir boosted doses; however, peak concentrations were slightly decreased (Bergshoeff, 2004). A pediatric clinical trial that used these same doses demonstrated good virologic efficacy; however, 4 of 21 patients developed nephrolithiasis; a high rate of overall side effects and intolerance to the dosing regimen was observed (Fraaij, 2007).  Further studies are needed.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11382985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 10 mg/mL oral solution may be prepared using capsules. First, prepare a 100 mg/mL indinavir concentrate by adding the contents of fifteen 400 mg capsules and 60 mL purified water to a 100 mL amber glass bottle. Place bottle in an ultrasonic bath filled with water at 37&deg;C for 60 minutes, stirring the solution every 10 minutes. Filter solution; wash bottle and filter with 6 mL purified water; cool solution to room temperature. Add 50 mL of 100 mg/mL indinavir concentrate to 360 mL viscous sweet base, 90 mL simple syrup, 1.8 g citric acid, 45 mg azorubine, 0.1M sodium hydroxide solution to pH 3, and 12 drops of lemon oil, to make a final volume of 500 mL. Mix to a uniform solution. Label &ldquo;refrigerate&rdquo;. Stable for 2 weeks refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Hugen PW, Burger DM, ter Hofstede HJ, et al, \"Development of an Indinavir Oral Liquid for Children,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2000, 57(14):1332-9.",
"     <span class=\"pubmed-id\">",
"      10918923",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bergshoeff AS, Fraaij PL, van Rossum AM, et al, \"Pharmacokinetics of Indinavir Combined With Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Children,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2004, 48(5):1904-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28281/abstract-text/15105157/pubmed\" id=\"15105157\" target=\"_blank\">",
"        15105157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Briars LA, Hilao JJ, and Kraus DM, &ldquo;A Review of Pediatric Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Journal of Pharmacy Practice",
"      </i>",
"      , 2004, 17(6):407-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" October 14, 2011, 1-167. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" August 11, 2011. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fletcher CV, Brundage RC, Remmel RP, et al, &ldquo;Pharmacologic Characteristics of Indinavir, Didanosine, and Stavudine in Human Immunodeficiency Virus-Infected Children Receiving Combination Therapy,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2000, 44(4):1029-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28281/abstract-text/10722507/pubmed\" id=\"10722507\" target=\"_blank\">",
"        10722507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fraaij PL, Verweel G, van Rossum AM, et al, \"Indinavir/Low-Dose Ritonavir Containing HAART in HIV-1 Infected Children has Potent Antiretroviral Activity, but Is Associated With Side Effects and Frequent Discontinuation of Treatment,\"",
"      <i>",
"       Infection",
"      </i>",
"      , 2007, 35(3):186-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28281/abstract-text/17565462/pubmed\" id=\"17565462\" target=\"_blank\">",
"        17565462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gatti G, Vigano' A, Sala N, et al, &ldquo;Indinavir Pharmacokinetics and Pharmacodynamics in Children With Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2000, 44(3):752-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28281/abstract-text/10681350/pubmed\" id=\"10681350\" target=\"_blank\">",
"        10681350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mueller BU, Smith S, Sleasman J, et al, &ldquo;A Phase I/II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection,&rdquo;",
"      <i>",
"       Eleventh International Conference on AIDS",
"      </i>",
"      , Vancouver, Canada, 1996.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Piscitelli SC, Burstein AH, Chaitt D, et al, &ldquo;Indinavir Concentrations and St John's Wort,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 355(9203):547-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28281/abstract-text/10683007/pubmed\" id=\"10683007\" target=\"_blank\">",
"        10683007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stein DS, Fish DG, Bilello JA, et al, &ldquo;A 24-Week Open-Label Phase I/II Evaluation of the HIV Protease Inhibitor MK-639 (Indinavir),&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1996, 10(5):485-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28281/abstract-text/8724039/pubmed\" id=\"8724039\" target=\"_blank\">",
"        8724039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Public Health Service, &ldquo;Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-9):1-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28281/abstract-text/16195697 /pubmed\" id=\"16195697 \" target=\"_blank\">",
"        16195697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Rossum AM, de Groot R, Hartwig NG, et al, \"Pharmacokinetics of Indinavir and Low-Dose Ritonavir in Children With HIV-1 Infection,\"",
"      <i>",
"       AIDS",
"      </i>",
"      , 2000, 14(14):2209-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28281/abstract-text/11061667/pubmed\" id=\"11061667\" target=\"_blank\">",
"        11061667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Rossum AM, Niesters HG, Geelen SP, et al, &ldquo;Clinical and Virologic Response to Combination Treatment With Indinavir, Zidovudine, and Lamivudine in Children With Human Immunodeficiency Virus-1 Infection: A Multicenter Study in the Netherlands. On Behalf of the Dutch Study Group for Children with HIV-1 Infections,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2000, 136(6):780-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/39/28281/abstract-text/10839877 /pubmed\" id=\"10839877 \" target=\"_blank\">",
"        10839877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12939 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28281=[""].join("\n");
var outline_f27_39_28281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182536\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182537\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053391\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053383\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182511\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182497\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053395\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053386\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053394\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182580\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182579\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053399\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053382\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053381\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182568\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182505\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053401\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182507\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182520\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053390\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053380\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053398\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053388\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6052683\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11382985\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12939\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12939|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=related_link\">",
"      Indinavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/28/3525?source=related_link\">",
"      Indinavir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_39_28282="Transfusion-related acute lung injury (TRALI)";
var content_f27_39_28282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transfusion-related acute lung injury (TRALI)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/39/28282/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/39/28282/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/39/28282/contributors\">",
"     Daryl J Kor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/39/28282/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/39/28282/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/39/28282/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/39/28282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/39/28282/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/39/28282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion-related acute lung injury (TRALI) is a rare but potentially fatal complication of blood product transfusion. TRALI has been defined by both a National Heart, Lung, and Blood Institute (NHLBI) working group as well as a Canadian Consensus Conference, as new acute lung injury",
"    <span class=\"nowrap\">",
"     (ALI)/acute",
"    </span>",
"    respiratory distress syndrome (ARDS) occurring during or within six hours after blood product administration (",
"    <a class=\"graphic graphic_table graphicRef64212 \" href=\"UTD.htm?7/15/7420\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. When a clear temporal relationship to an alternative risk factor for",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    coexists, a formal diagnosis of TRALI cannot be made. In these circumstances, the diagnostic terminology to be used is &ldquo;possible TRALI.&rdquo;",
"   </p>",
"   <p>",
"    Prior to the institution of TRALI risk mitigation strategies, plasma components and apheresis platelet concentrates conferred the highest risk of TRALI per component. Currently, due to transfusion of a much larger number of red cell units compared with plasma and platelets, the largest number of TRALI-related deaths in the United States and other developed countries occur with red blood cell transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, risk factors, clinical features, management, and prevention strategies for TRALI are presented here. General issues related to blood transfusion, other reactions to transfusion therapies, and general issues related to acute lung injury are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"       \"Immunologic blood transfusion reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link\">",
"       \"Transfusion reactions caused by chemical and physical agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link\">",
"       \"Noncardiogenic pulmonary edema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link\">",
"       \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1588903\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical estimates suggest that TRALI occurs at a rate of approximately 0.04 to 0.1 percent of transfused patients or in approximately 1 in 5000 transfused blood components [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. However, the true incidence of TRALI is not known, largely due to poor syndrome recognition, the reliance on passive reporting rather than active surveillance strategies, and the inclusion of cases that did not meet the NHLBI or Canadian Consensus Conference definitions of TRALI in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/3,8-11\">",
"     3,8-11",
"    </a>",
"    ]. Additionally, due to the contribution of specific recipient risk factors, TRALI incidence is also likely to depend on the population of interest. As an example, estimates suggest that the rate of TRALI in critically ill populations may reach 5 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1588938\">",
"     'Recipient risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Importantly, the incidence of TRALI has decreased dramatically following the institution of TRALI mitigation strategies for transfused plasma and platelet components that were instituted in the mid to late 2000s. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an illustration of this, TRALI cases were identified using a prospective systematic method at a rate of 0.0081 percent (ie, 1 in 12,345) in the year 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. This was substantially lower than the incidence rate of 0.0257 percent (ie, 1 in 3891) in the year 2006, determined with the same case detection strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Even though case surveillance in this study was active and prospective, under-reporting still may have occurred, as has been the case with other published estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TRALI is the leading cause of transfusion-related mortality in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/3\">",
"     3",
"    </a>",
"    ]. Historical estimates for TRALI&ndash;associated mortality have ranged from 5 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/16\">",
"     16",
"    </a>",
"    ]. However, evidence from large hemovigilance networks suggests higher mortality rates in the range of 13 to 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/8,17-19\">",
"     8,17-19",
"    </a>",
"    ]. Not surprisingly, the mortality rate for",
"    <span class=\"nowrap\">",
"     TRALI/possible",
"    </span>",
"    TRALI in critically ill populations appears substantially higher, in the range of 35 to 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1588910\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific risk factors for TRALI can be divided conceptually into recipient risk factors and blood component risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1588938\">",
"    <span class=\"h2\">",
"     Recipient risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;TRALI has been reported to occur in essentially all age groups and equally in both sexes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The presence of an underlying condition such as recent surgery, cytokine treatment, massive blood transfusion, and active infection have been implicated in some, but not all, studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/4,17,18,21-26\">",
"     4,17,18,21-26",
"    </a>",
"    ]. The critically ill appear to be at highest risk for TRALI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/12,13,27\">",
"     12,13,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating TRALI risk factors are limited by a relatively small number of TRALI cases available for analysis and the use of varied diagnostic criteria. The following studies are illustrative of the available data:",
"   </p>",
"   <p>",
"    A multicenter prospective cohort investigation using active surveillance strategies for TRALI detection identified recipient risk factors for TRALI in 89 cases compared with 164 matched transfused controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/15\">",
"     15",
"    </a>",
"    ]. The following pre-transfusion TRALI risk factors were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver transplantation surgery",
"     </li>",
"     <li>",
"      Chronic alcohol abuse",
"     </li>",
"     <li>",
"      Shock",
"     </li>",
"     <li>",
"      Higher peak airway pressure while being mechanically ventilated",
"     </li>",
"     <li>",
"      Current smoking",
"     </li>",
"     <li>",
"      Higher interleukin (IL)-8 levels",
"     </li>",
"     <li>",
"      Positive fluid balance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a nested case-control study evaluating patients in an intensive care unit (ICU) for more than 48 hours, risk factors for",
"    <span class=\"nowrap\">",
"     TRALI/possible",
"    </span>",
"    TRALI included emergency cardiac surgery, hematologic malignancy, massive transfusion, sepsis, mechanical ventilation, and a high Acute Physiology and Chronic Health Evaluation II (APACHE II) score [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/12\">",
"     12",
"    </a>",
"    ]. In another study evaluating critically ill patients in a medical ICU, sepsis, liver disease, and a history of alcohol abuse were more common in transfusion recipients who developed",
"    <span class=\"nowrap\">",
"     TRALI/possible",
"    </span>",
"    TRALI than in transfused controls without respiratory compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17014590\">",
"    <span class=\"h2\">",
"     Blood component risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all blood components have been associated with TRALI. This includes transfused whole blood derived platelets, cryoprecipitate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/4\">",
"     4",
"    </a>",
"    ], and granulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/28\">",
"     28",
"    </a>",
"    ], as well as intravenous immunoglobulin preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], and allogeneic stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/2,16,22,31\">",
"     2,16,22,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Donor gender and high-plasma-volume blood components",
"      </strong>",
"      &mdash; Though TRALI has been associated with virtually all blood products, high-plasma-volume components such as plasma, apheresis platelet concentrates, and whole blood have been consistently shown to carry the greatest risk per component or per transfusion episode [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/8,11,18,32\">",
"       8,11,18,32",
"      </a>",
"      ]. The volume of plasma passively infused that results in TRALI is unknown, but may be as small as 10 to 20 mL [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/33\">",
"       33",
"      </a>",
"      ]. Further studies have demonstrated a role for female sex and increased parity of the donor in the risk for TRALI [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/15,34-36\">",
"       15,34-36",
"      </a>",
"      ]. The role of these factors was illustrated in a multicenter prospective cohort investigation utilizing active TRALI surveillance strategies, which identified the following",
"      <span class=\"nowrap\">",
"       donor/blood",
"      </span>",
"      component risk factors for TRALI [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/15\">",
"       15",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Plasma or whole blood from female donors",
"     </li>",
"     <li>",
"      Increased volume of highly reactive transfused anti-human leukocyte antigen (HLA) Class II antibody with specificity for a cognate recipient HLA antigen (ie, antibodies for which the recipient had the corresponding HLA antigen)",
"     </li>",
"     <li>",
"      Increased volume of transfused anti-human neutrophil antigen (HNA) antibody [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/15\">",
"       15",
"      </a>",
"      ]",
"      <br/>",
"      <br/>",
"      The presence of non-cognate anti-HLA Class II antibodies, weaker cognate anti-HLA Class II antibodies, or any anti-HLA Class I antibody were not associated with TRALI in this study. However, other case reports suggest that anti-HLA Class I antibodies can cause TRALI [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/8,37\">",
"       8,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Red blood cell storage duration",
"      </strong>",
"      &mdash; Although a longer duration of red blood cell storage has been suggested to increase the risk of TRALI, two randomized clinical trials and two large observational studies have not confirmed this association [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/15,38-41\">",
"       15,38-41",
"      </a>",
"      ]. In aggregate, the available evidence suggests that the duration of red blood cell storage is not a major risk factor in the development",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity of TRALI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The generally accepted theory for TRALI pathogenesis is that it occurs via a",
"    <strong>",
"     two-hit",
"    </strong>",
"    mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/4,42,43\">",
"     4,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Neutrophil sequestration and priming",
"      </strong>",
"      &mdash; The first hit involves neutrophil sequestration and priming in the lung microvasculature, due to recipient factors such as endothelial injury. Priming refers to shifting of neutrophils to a state where they will respond to an otherwise innocuous or weak signal [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/44\">",
"       44",
"      </a>",
"      ]. Endothelial cells are thought to be responsible for both the neutrophil sequestration (through adhesion molecules) and priming (through cytokine release). Generally these events are coupled and exist prior to the transfusion, although there may be circumstances in which they can occur as a result of the transfusion. (See",
"      <a class=\"local\" href=\"#H1588938\">",
"       'Recipient risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Neutrophil activation",
"      </strong>",
"      &mdash; The second hit is",
"      <strong>",
"      </strong>",
"      activation of recipient neutrophils by a factor in the blood product. Activation is associated with the release from neutrophils of cytokines, reactive oxygen species, oxidases, and proteases that damage the pulmonary capillary endothelium. This damage causes inflammatory (non-hydrostatic) pulmonary edema. Transfused factors responsible for host neutrophil activation can include antibodies in the blood component directed against recipient antigens, or soluble factors such as bioactive lipids that can activate neutrophils. Donor anti-leukocyte antibodies can bind to antigens on recipient neutrophils or other cells; this is referred to by some authors as immune TRALI [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/45-48\">",
"       45-48",
"      </a>",
"      ]. Bioactive lipids and other soluble factors in the transfused blood component can act as biological response modifiers (BRMs); TRALI resulting from these non-antibody BRMs is sometimes referred to as non-immune TRALI [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17014590\">",
"       'Blood component risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical observations supporting the two-hit theory come from retrospective studies demonstrating that most transfused blood products containing HLA antibody do not cause TRALI, even if a cognate recipient antigen is present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/49\">",
"     49",
"    </a>",
"    ]. In retrospective studies, TRALI was detected in only 2.9 percent of individuals who received blood products from donors previously implicated in causing TRALI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/37,49-52\">",
"     37,49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case of fatal TRALI, the implicated donor was a multiparous female who had made 290 previous plasma apheresis donations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/9\">",
"     9",
"    </a>",
"    ]. Of 36 patients who had received her plasma in the prior two years, 15 experienced transfusion reactions with pulmonary symptoms, and 21 (58 percent) did not, again highlighting that factors from the transfusion alone are insufficient to cause TRALI. In this case, the donor had antibodies against a leukocyte antigen (HNA-3a) present in more than 95 percent of the general population that has been associated with severe often fatal TRALI cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/53\">",
"     53",
"    </a>",
"    ]. In another case, TRALI occurred in a recipient of a single lung transplant only in the transplanted lung, and one of the blood products the donor received contained anti-HLA Class I antibodies that matched an HLA antigen present only in the transplanted lung [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of TRALI caused by antibodies versus BRMs remains undetermined and is likely to vary by the type of component transfused, with antibody-mediated mechanisms explaining the majority of the cases due to plasma, and non-immune BRMs responsible for most cases from red blood cell transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/18,55,56\">",
"     18,55,56",
"    </a>",
"    ]. The widely stated statistic that 80 to 85 percent of TRALI cases are due to the antibody-mediated mechanism is likely influenced by publication bias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/57\">",
"     57",
"    </a>",
"    ]. Of note, a case series comparing BRM-mediated TRALI with antibody-mediated TRALI suggests that BRM-mediated TRALI is a less severe condition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second model related to the two-hit theory is the threshold model. This model agrees that two hits are usually necessary for TRALI, but allows for the possibility that in some cases the second hit is so strong that an initial priming event is not required [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/43,58,59\">",
"     43,58,59",
"    </a>",
"    ]. This theory explains TRALI cases that have occurred in otherwise healthy individuals who have received fresh frozen plasma (FFP) as a treatment for reversing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation.",
"   </p>",
"   <p>",
"    Several observations support the role of neutrophils as the major effector cells in TRALI. Neutrophil activation occurs in animal models of TRALI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/60-65\">",
"     60-65",
"    </a>",
"    ]. Transient neutropenia indicative of pulmonary sequestration has been seen in patients in the early phase of TRALI, whereas TRALI is rarely seen in neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/37,66-70\">",
"     37,66-70",
"    </a>",
"    ]. In an autopsy case, postmortem examination within two hours of TRALI onset revealed aggregates of neutrophils within the pulmonary capillaries associated with inflammatory edema and endothelial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple mechanisms of neutrophil activation in TRALI have been proposed. As an example, antibodies to human leukocyte antigen (HLA) Class I and human neutrophil antigens (HNA) may bind to recipient neutrophils and trigger their activation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/58,59,72,73\">",
"     58,59,72,73",
"    </a>",
"    ]. It has been known for years that female donors, due to exposure to fetal alloantigens during pregnancy, have a much higher prevalence of anti-HLA antibodies than do male donors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. While anti-HNA antibodies account for only a small percentage of TRALI cases from most countries (&lt;5 percent), in Germany these constitute a higher percentage (28 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/19\">",
"     19",
"    </a>",
"    ]. Antibodies directed against the HNA 3a antigen have been associated with a substantial number of severe or fatal TRALI cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TRALI can also be associated with donor antibodies directed against HLA Class II, which is primarily expressed on antigen-presenting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/44,59\">",
"     44,59",
"    </a>",
"    ]. These antibodies may bind to HLA Class II antigens on monocytes, causing release of cytokines that in turn activate primed neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/73,78-80\">",
"     73,78-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the second hit for neutrophil activation is a biological response modifier (BRM) rather than an antibody, the BRM is believed to activate neutrophils directly. Most of the work implicating these substances has come from in vitro and animal studies, and has implicated lysophosphatidylcholines (from white blood cells and platelets) and neutral lipids (from the breakdown of red cell membranes) in neutrophil activation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/4,23,42,63,64,81-83\">",
"     4,23,42,63,64,81-83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic clinical presentation of TRALI is the sudden onset of hypoxemic respiratory insufficiency during or shortly after the transfusion of a blood product (",
"    <a class=\"graphic graphic_table graphicRef64212 \" href=\"UTD.htm?7/15/7420\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Symptoms may be delayed as long as six hours, but usually begin within one to two hours of initiating the blood component infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. Indeed, the majority of cases occur within minutes of initiating a transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/4\">",
"     4",
"    </a>",
"    ]. A number of additional signs and symptoms associated with noncardiogenic pulmonary edema and inflammation have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/1,18,22,69,70,84,85\">",
"     1,18,22,69,70,84,85",
"    </a>",
"    ]. As an example, in a retrospective study of 49 TRALI cases, the most common signs and symptoms and their approximate frequencies were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/18\">",
"     18",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoxemia: in an intubated patient this could manifest as a change in oxygenation or increased oxygen requirements (100 percent, by definition)",
"     </li>",
"     <li>",
"      Pulmonary infiltrates on chest radiography (100 percent, by definition; the cardiac silhouette is classically normal)",
"     </li>",
"     <li>",
"      If previously intubated, pink frothy airway secretions from the endotracheal tube (56 percent)",
"     </li>",
"     <li>",
"      Fever (33 percent)",
"     </li>",
"     <li>",
"      Hypotension (32 percent)",
"     </li>",
"     <li>",
"      Cyanosis (25 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other reports have also noted tachypnea, tachycardia, and elevated peak and plateau airway pressures in intubated patients. An acute, transient drop in the peripheral neutrophil count (consistent with sequestration of large numbers of neutrophils in the lungs) has also been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TRALI should be considered whenever a patient develops hypoxemic respiratory insufficiency during or shortly after transfusion of any blood product [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/1\">",
"     1",
"    </a>",
"    ]. TRALI is a clinical diagnosis made using the criteria outlined by the NHLBI&rsquo;s working group on TRALI as well as the Canadian Consensus Conference on TRALI (",
"    <a class=\"graphic graphic_table graphicRef64212 \" href=\"UTD.htm?7/15/7420\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These criteria require the presence of",
"    <strong>",
"     new",
"    </strong>",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    occurring during or within six hours after blood product administration, documented by hypoxemia and an abnormal chest radiograph. Hypoxemia is documented when oxygen saturation is &le;90 percent on room air or the",
"    <span class=\"nowrap\">",
"     PaO2/FIO2",
"    </span>",
"    ratio is &lt;300 mmHg, although other signs of hypoxia can also satisfy this criterion. Frontal chest radiograph must demonstrate bilateral pulmonary infiltrates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link&amp;anchor=H3#H3\">",
"     \"Noncardiogenic pulmonary edema\", section on 'Definition of noncardiogenic pulmonary edema'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a clear temporal relationship to an alternative risk factor for",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    coexists, a formal diagnosis of TRALI cannot be made. In these circumstances, &ldquo;possible TRALI&rdquo; is the more appropriate diagnosis. Use of these separate diagnostic categories (ie, TRALI and possible TRALI) allows for their separate reporting in surveillance systems, which may facilitate differential approaches to donor investigation and management, as well as targeting research programs to either (or both) groups of patients. (See",
"    <a class=\"local\" href=\"#H1592582\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When TRALI is suspected, the treating physician should evaluate the recipient&rsquo;s vital signs, assess the extent of hypoxemia, and obtain a chest radiograph. Pulse oximetry is often sufficient, but arterial blood gas analysis may be warranted in more severe cases. Consideration of the likelihood of other potential causes for the respiratory distress (eg, cardiovascular compromise, anaphylaxis, sepsis, exacerbation of underlying lung disease or atelectasis) should guide appropriate clinician-initiated laboratory testing. (See",
"    <a class=\"local\" href=\"#H1592582\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When a transfusion reaction such as TRALI is suspected, the transfusion should be stopped immediately and the case should be promptly reported to the hospital transfusion medicine",
"    <span class=\"nowrap\">",
"     service/blood",
"    </span>",
"    bank. Based on the details of the case, the blood bank will initiate a transfusion reaction workup, which will usually include drawing a sample from the patient for appropriate laboratory tests. These may include complete blood count, bilirubin, haptoglobin, direct antiglobulin (Coombs) test, brain natriuretic peptide (BNP) or N-terminal (NT)-Pro-BNP, and HLA antigen typing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If TRALI is suspected, the blood bank will compile a list of blood products transfused within the previous six hours and forward this list to the blood supplier. The blood supplier will then follow its procedures to recall these donors and initiate testing for HLA and possibly HNA antibodies. However, these results will not be available for several weeks. Identifying the implicated donor(s) and deferring that individual from future high plasma volume donation requires cooperation between the clinician (to provide accurate clinical information), the hospital transfusion medicine service, and the blood supplier. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1592582\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of TRALI includes other conditions that can manifest with respiratory distress following transfusion. This includes other causes of",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    as well as other transfusion reactions. These conditions are described in more detail in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17314495\">",
"    <span class=\"h2\">",
"     Possible TRALI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A formal diagnosis of TRALI requires the absence of temporal relationships with additional risk factors for",
"    <span class=\"nowrap\">",
"     ALI/ARDS,",
"    </span>",
"    such as aspiration, pneumonia, toxic inhalation, lung contusion, trauma, burn injury, and pancreatitis. When other criteria for TRALI are met but additional risk factors for",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    are also present (",
"    <a class=\"graphic graphic_table graphicRef64212 \" href=\"UTD.htm?7/15/7420\">",
"     table 1",
"    </a>",
"    ), a diagnosis of TRALI cannot be made and the term &ldquo;possible TRALI&rdquo; is preferred. This can also be designated as TRALI with ALI risk factors. Although massive transfusion has historically been recognized as a risk factor for",
"    <span class=\"nowrap\">",
"     ALI/ARDS,",
"    </span>",
"    a diagnosis of TRALI should be made in this circumstance provided that no other",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    risk factors were present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17314533\">",
"    <span class=\"h2\">",
"     TACO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion-associated circulatory overload (TACO) is another cause of transfusion-related respiratory insufficiency. Though it is most commonly reported in elderly patients and small children, TACO can occur in all age ranges. Additional risk factors for TACO include compromised cardiac function, positive fluid balance, and rapid blood product administration. TACO appears to occur more frequently in surgical or intensive care settings, where large fluid volumes and blood are administered. Characteristic features and differentiating factors for TRALI versus TACO are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef86939 \" href=\"UTD.htm?20/44/21196\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link&amp;anchor=H2#H2\">",
"     \"Transfusion reactions caused by chemical and physical agents\", section on 'Transfusional volume overload (TACO)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a general rule, TRALI is more likely to be associated with fever, hypotension, and exudative pulmonary infiltrates, and less likely to respond to diuresis. In contrast, TACO is more likely to be associated with findings suggesting volume overload (eg, positive fluid balance, elevated jugular venous pressure, elevated pulmonary artery occlusion pressure) or poor cardiac function (eg, history of congestive heart failure, reduced left ventricular ejection fraction, or diastolic dysfunction). Similarly, elevated systolic blood pressures near the time of dyspnea onset, a widened pulmonary vascular pedicle width or increased cardiothoracic ratio on chest radiography,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased circulating levels of brain natriuretic peptide (BNP) or N-terminal (NT)-Pro-BNP suggest a diagnosis of TACO rather than TRALI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/87-92\">",
"     87-92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differentiating TRALI from TACO can be a significant challenge, particularly as both may coexist [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/87,93,94\">",
"     87,93,94",
"    </a>",
"    ]. In such cases, pulmonary findings may be due to a combination of hydrostatic (eg, TACO) and non-hydrostatic (eg, TRALI) lung edema. Indeed, studies show that approximately 30 percent of",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    patients have at least mild evidence of left atrial hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/95\">",
"     95",
"    </a>",
"    ]. In these circumstances,",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    is diagnosed in the presence of fluid overload based on clinical judgment that the degree of fluid overload is not sufficient to explain the extent of hypoxemia and pulmonary infiltrates. This type of mixed picture may be more likely to occur in intensive care unit (ICU)",
"    <span class=\"nowrap\">",
"     patients.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13037582\">",
"    <span class=\"h2\">",
"     Other causes of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALI/ARDS",
"    may be present prior to the initiation of transfusion therapies or may arise more than six hours after a transfusion episode. In these cases, ARDS is the more appropriate diagnosis. Of note, a consensus conference has recommended eliminating the term ALI, which has historically described lung injury with less severe hypoxemia (ie,",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    &lt;300 but &gt;200). Rather, it is now recommended that such cases be classified as &ldquo;mild ARDS&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/96\">",
"     96",
"    </a>",
"    ]. In such cases, it is recognized that the administration of blood products may in fact contribute to",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    development even though a formal diagnosis of TRALI cannot be made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1592784\">",
"    <span class=\"h2\">",
"     Other transfusion reactions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hemolytic transfusion reactions",
"      </strong>",
"      &mdash; Hemolytic transfusion reactions can cause respiratory distress, but fever and chills tend to predominate in hemolytic transfusion reactions more than in TRALI. Hemolytic reactions are typically due to ABO incompatibility, and pink serum or hemoglobinuria may be seen due to intravascular hemolysis. The direct antiglobulin (Coombs) test will be positive in hemolytic reactions, but not in TRALI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H7#H7\">",
"       \"Immunologic blood transfusion reactions\", section on 'Acute hemolytic reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Anaphylaxis",
"      </strong>",
"      &mdash; Anaphylaxis can cause respiratory distress similar to TRALI, but anaphylaxis is more often associated with airway signs and symptoms such as stridor, cough, wheezing, nasal congestion, and bronchospasm. Anaphylaxis is also more often associated with a new rash, gastrointestinal symptoms such as nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting, and shock. Notably, however, the latter may be seen in TRALI as well. The cause of most transfusion-associated anaphylactic reactions is unknown, but one recognized etiology is transfusion of IgA-containing products to an IgA deficient recipient who has antibodies to IgA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H13#H13\">",
"       \"Immunologic blood transfusion reactions\", section on 'Anaphylactic reactions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sepsis",
"      </strong>",
"      &mdash; Severe sepsis and septic shock are often associated with respiratory distress, fever, and hypotension. Evidence for an active infectious process (leukocytosis, fever, positive microbiology) suggests the diagnosis of severe sepsis or septic shock rather than TRALI. Transfusion-associated sepsis is generally associated with the administration of bacterially contaminated platelets. In this case, evaluation of the transfusion by the blood bank will typically identify a contaminating microorganism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H382870592#H382870592\">",
"       \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Complications of platelet transfusion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11655881\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;If",
"    <span class=\"nowrap\">",
"     TRALI/possible",
"    </span>",
"    TRALI is suspected, the transfusion should be discontinued immediately. Physicians should alert the blood bank and initiate an evaluation for a transfusion reaction. This is important for the protection of future recipients as well as for TRALI laboratory testing and work-up. This initial evaluation is described in more detail above. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Management of the patient with",
"    <span class=\"nowrap\">",
"     TRALI/possible",
"    </span>",
"    TRALI is supportive, with oxygen supplementation for the correction of hypoxemia being the cornerstone of treatment. Non-invasive respiratory support with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) may be sufficient in less severe cases, but endotracheal intubation with invasive mechanical ventilation is often required [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/13\">",
"     13",
"    </a>",
"    ]. The available evidence suggests that most patients who develop either TRALI or possible TRALI will require ventilatory support (approximately 70 to 80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/5,12,13,97\">",
"     5,12,13,97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11655890\">",
"    <span class=\"h2\">",
"     Ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no prospective clinical investigations on strategies for managing mechanical ventilation in patients with TRALI, and it is generally believed that ventilator management should be guided by the same principles used in patients with other forms of",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/98\">",
"     98",
"    </a>",
"    ]. The successful application of more extreme life support interventions, such as extracorporeal membrane oxygenation, has also been described in TRALI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=see_link\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11655897\">",
"    <span class=\"h2\">",
"     Hemodynamic support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with TRALI often present with hypovolemia and associated hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/100\">",
"     100",
"    </a>",
"    ]. The initial goal of hemodynamic management is to ensure adequate end-organ perfusion. This may be achieved with fluid resuscitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasoactive support. Caution should be taken with early empiric administration of diuretic therapy, as it may result in hypotension in those who were initially hemodynamically stable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/16,101\">",
"     16,101",
"    </a>",
"    ]. However, for patients with sustained hypoxemia and demonstrated hemodynamic stability, administration of diuretic therapy may be a reasonable intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11655904\">",
"    <span class=\"h2\">",
"     Steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous corticosteroids have been extensively studied in the setting of",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    with mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/16,102,103\">",
"     16,102,103",
"    </a>",
"    ]. In regards to TRALI, there are isolated case reports supporting high-dose corticosteroids in the treatment of this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/16,104\">",
"     16,104",
"    </a>",
"    ]. However, the efficacy of corticosteroids has not been tested in prospective clinical studies, and the limited anecdotal evidence is unconvincing. Thus, we do not recommend the routine use of corticosteroids when TRALI is suspected. Moreover, due to evidence suggesting harm when initiating corticosteroids late in the course of",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    (&gt;14 days after syndrome onset) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/16,101,105\">",
"     16,101,105",
"    </a>",
"    ], we advise against the use of corticosteroid therapy when the lung injury is fully established and has been present for more than two weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link&amp;anchor=H16#H16\">",
"     \"Novel therapies for the acute respiratory distress syndrome\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11655911\">",
"    <span class=\"h2\">",
"     Investigational strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the therapies described above, a number of additional",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    and, by association, TRALI treatment and prevention strategies have been proposed and are under various stages of investigation. Examples include HMG-CoA reductase inhibitors (statins) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/106\">",
"     106",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/106,107\">",
"     106,107",
"    </a>",
"    ], and alternatives to allogeneic blood products (eg, RBC substitutes, prothrombin complex concentrates, fibrinogen concentrates, and activated factor VII). However, at present, none of these therapies has sufficient evidence to justify its use as a routine TRALI prevention or treatment measure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11655918\">",
"    <span class=\"h2\">",
"     Additional transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who recover from TRALI do not appear to be at increased risk for recurrent episodes following transfusions from other donors; however, published experience is limited. Survivors of TRALI can receive additional blood products in the future, and transfusion of needed blood products should not be withheld [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/16,22\">",
"     16,22",
"    </a>",
"    ]. Importantly, however, individuals should",
"    <strong>",
"     not",
"    </strong>",
"    receive plasma-containing blood products from the implicated donor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/108-111\">",
"     108-111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17314915\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial descriptions detailing the clinical course for TRALI suggested quick resolution of hypoxemia, generally within 24 to 48 hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the majority of patients who develop TRALI will require ICU admission and ventilator support [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. For those requiring mechanical ventilation, these early reports described a mean duration of ventilatory support lasting approximately 40 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, subsequent evidence suggests that most cases will require respiratory support for a longer period (eg, approximately 3 to 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These more contemporary data frequently report composite outcomes from cases of TRALI and possible TRALI and limit the study population to the critically ill. Such cases are likely to represent the more severe end of the clinical spectrum. In contrast, milder cases of TRALI",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    possible TRALI may go undiagnosed or unreported. As such, the clinical presentation, need for life-support interventions, and outcomes for patients with TRALI",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    possible TRALI remain incompletely defined.",
"   </p>",
"   <p>",
"    Mortality rates associated with",
"    <span class=\"nowrap\">",
"     TRALI/possible",
"    </span>",
"    TRALI have been reported to be as high as 41 to 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/7,12,13,97\">",
"     7,12,13,97",
"    </a>",
"    ]. Again, however, these more extreme reports generally originate from critically ill study populations with TRALI and possible TRALI combined into a single composite outcome. In contrast, lower mortality rates (5 to 10 percent) are typically described for TRALI itself [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/21,112\">",
"     21,112",
"    </a>",
"    ]. Although limited information is available, it appears that most survivors will recover to their baseline pulmonary function, and they can safely receive additional blood products in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/1,16,22\">",
"     1,16,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following all cases of TRALI and some cases of possible TRALI, the blood bank and the blood collection facility should investigate all of the associated donors for the presence of anti-human leukocyte antigen (HLA) and possibly anti-human neutrophil antigen (HNA) antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/113\">",
"     113",
"    </a>",
"    ], with the goal of identifying donors who should be deferred from future donations. In reality, the number of donors investigated may be more limited and the laboratory work-up performed by transfusion services may vary depending upon the number of donors in a case; the availability of donor samples; the availability of neutrophil antibody testing, which is restricted to a few specialty laboratories in the US; and the availability of a recipient sample for HLA antigen typing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/1,114,115\">",
"     1,114,115",
"    </a>",
"    ]. Some laboratories in Europe also perform leukocyte cross-matching as part of the evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A donor who is shown to have leukocyte antibodies that match or are likely to match a recipient&rsquo;s leukocyte antigens is classified as an implicated donor and is, at minimum, deferred from future plasma apheresis or platelet apheresis. Furthermore, most blood banks will defer an implicated donor from any type of blood donation; this is particularly true if the donor has anti-HNA 3a [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, several general blood donor management strategies are in use to reduce the incidence of TRALI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/1,8,32,114,116-128\">",
"     1,8,32,114,116-128",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adherence to current guidelines of blood component utilization, especially for plasma, to decrease recipient exposure to transfused units.",
"     </li>",
"     <li>",
"      Deferral of donors implicated in a TRALI reaction.",
"     </li>",
"     <li>",
"      For high plasma volume components (eg, FFP, plasma frozen within 24 hours of phlebotomy [FP-24], plasma, cryo-reduced [cryo-poor] plasma, apheresis platelets, buffy coat derived platelet pools resuspended in plasma from a single donor, and whole blood), selection of donors who are less likely to be alloimmunized to leukocytes.",
"     </li>",
"     <li>",
"      Use of pooled solvent detergent plasma as an alternative to FFP.",
"     </li>",
"     <li>",
"      Testing of parous apheresis donors of platelets or plasma for anti-HLA antibodies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11655925\">",
"    <span class=\"h2\">",
"     Deferral of multiparous female donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been well established that donors implicated in TRALI cases are more likely to be female and more likely to be multiparous [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/15,35,36\">",
"     15,35,36",
"    </a>",
"    ]. These factors resulted in the implementation of a new TRALI risk mitigation policies during the mid to late 2000s throughout most of Europe and the United States, in which transfusable plasma units were predominantly obtained from male donors, thereby avoiding the transfusion of plasma units from female donors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/8,11,119-121,129\">",
"     8,11,119-121,129",
"    </a>",
"    ]. This policy is feasible for plasma transfusion because the number of plasma units derived from whole blood or apheresis collections is in excess of demand. In contrast, this policy is not feasible for apheresis platelet transfusion where restriction of units to male donors would seriously jeopardize the platelet supply.",
"   </p>",
"   <p>",
"    The importance of these policies is illustrated by a large multicenter study conducted under the auspices of the National Heart, Lung, and Blood Institute (NHLBI) Retrovirology and Donor Epidemiology Program II (REDS-II) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/127\">",
"     127",
"    </a>",
"    ]. This study, known as the Leukocyte Antibody Prevalence Study (LAPS), used modern flow cytometry techniques to assess the prevalence of HLA antibodies in almost 8000 volunteer blood donors. There was a dose-response increase in the frequency of anti-HLA antibodies according to parity, from 1.7 percent for never pregnant females to 32.2 percent for four or more pregnancies. Donors who themselves had received a blood transfusion, males, and never pregnant female donors all showed very low frequency of anti-HLA antibodies (in the range of 1 to 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/127,130\">",
"     127,130",
"    </a>",
"    ]. These data suggest that TRALI risk mitigation programs do not need to exclude plasma from never pregnant females or from donors with a previous transfusion history [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/121\">",
"     121",
"    </a>",
"    ]. Nevertheless, some European countries do not transfuse plasma obtained from donors who have themselves received a transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/119\">",
"     119",
"    </a>",
"    ]. These data also have helped to guide policies for HLA antibody testing of selected subpopulations of female plasma and platelet apheresis donors.",
"   </p>",
"   <p>",
"    The following observations support the effectiveness of sex-based risk reduction policies for reducing TRALI incidence from plasma transfusion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The UK National Blood Service, starting in late 2003, provided 80 to 90 percent of FFP from male donors. This was associated with a significant decrease in the risk of highly",
"      <span class=\"nowrap\">",
"       likely/probable",
"      </span>",
"      TRALI due to FFP (from 15.5 per million units issued from 1999 to 2004 to 3.2 per million from 2005 to 2006) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/8\">",
"       8",
"      </a>",
"      ]. There were 23 highly",
"      <span class=\"nowrap\">",
"       likely/probable",
"      </span>",
"      TRALI cases from all components in 2003, compared with three in 2010 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a four-year nested case-control study conducted from 2006 to 2009 at the University of California San Francisco and Mayo Clinic, TRALI incidence in 2006 (prior to implementation of risk reduction methods) was 0.0257 percent (1 in 3891); in 2009, after implementation of risk reduction policies for plasma products, TRALI incidence decreased to 0.0081 percent (1 in 12,345) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the US, annual TRALI fatalities attributed to plasma transfusion and reported to the FDA declined from a peak of 23 cases in 2006 to three cases in 2011 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/3\">",
"       3",
"      </a>",
"      ]. In the three years prior to introduction of the sex-based TRALI risk reduction policies, plasma accounted for 48 percent of the fatal cases reported to Food and Drug Administration (FDA), compared with 27 percent in the four years following their implementation (2008 to 2011). Similarly, cases of suspected TRALI from plasma reported to",
"      <sup>",
"      </sup>",
"      the American Red Cross National Hemovigilance Program decreased from a rate of approximately 20 probable TRALI cases per million plasma components in 2006 to approximately four per million plasma components in 2008. Moreover, in contrast to six TRALI fatalities related to plasma transfusion in 2006, there were none in 2008 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Germany, antibody-mediated TRALI from FFP transfusion decreased following the implementation of TRALI risk reduction policies. The rate fell from 12.71 per million units in 2006 to 2007 (pre-implementation of risk reduction policies) to 6.81 per million units in 2008 to 2009, during which there was partial implementation of risk reduction policies. With full implementation in 2010, no cases were reported [",
"      <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11655932\">",
"    <span class=\"h2\">",
"     Use of solvent detergent treated plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another strategy for TRALI risk reduction is to transfuse a pooled solvent detergent plasma product",
"    <span class=\"nowrap\">",
"     (S/D",
"    </span>",
"    plasma) in place of FFP. An",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma product was approved by the United States Food and Drug Administration in 2013, and",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma has been widely used in many European countries for many years. Notably, observational data from over 10 million",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma unit transfusions support the conclusion that this product does not cause TRALI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/123\">",
"     123",
"    </a>",
"    ]. A more controlled data set was provided by hemovigilance data collected in France in 2007 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/32\">",
"     32",
"    </a>",
"    ]. After transfusion of 212,000",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma units, there were no TRALI cases associated solely with",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma. In contrast, the TRALI incidence rate from FFP transfusion was 1 in 31,000 units. The absence of TRALI following transfusion of",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma has been attributed to the pooling of plasma from many different donors, resulting either in dilution of anti-HLA antibodies or in binding of such antibodies by soluble HLA antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/122,124\">",
"     122,124",
"    </a>",
"    ]. Notably, studies on 32 batches of SD plasma were unable to detect the presence of HLA antibodies in this product [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/122\">",
"     122",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogen inactivation of blood products\", section on 'Solvent-detergent method'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4500?source=see_link\">",
"     \"Solvent detergent treated fresh frozen plasma: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11655939\">",
"    <span class=\"h2\">",
"     Mitigating TRALI risk from platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some blood centers have implemented a policy of testing selected populations of platelet apheresis donors (eg, previously pregnant females, depending on the number of pregnancies) for anti-HLA antibodies and then redirecting anti-HLA antibody positive donors away from all high-plasma-volume donations, including platelet apheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/121\">",
"     121",
"    </a>",
"    ]. However, this strategy has not been universally adopted, and thus far there are no adequate data to evaluate its effect on TRALI incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/119\">",
"     119",
"    </a>",
"    ]. Another strategy considered for apheresis platelets is to resuspend the platelets in platelet additive solution (PAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/119\">",
"     119",
"    </a>",
"    ]. This reduces the plasma volume of the product by two-thirds. However, it is not currently known whether TRALI risk from the reduced plasma volume (still approximately 100 mL of plasma) will be decreased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11655954\">",
"    <span class=\"h2\">",
"     Mitigating TRALI risk from RBC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the success of TRALI risk reduction measures for plasma, the relative percentage of TRALI cases from red blood cells (RBC) has increased, such that the majority of current TRALI cases are associated with RBC transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/122\">",
"     122",
"    </a>",
"    ]. TRALI risk reduction measures appear to have had no effect on the frequency of TRALI cases associated with RBC transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/3,122,132\">",
"     3,122,132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data suggest that a non-antibody mediated mechanism, presumably a soluble biologic response modifier, may account for the majority of TRALI cases caused by RBC transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/18,55,56\">",
"     18,55,56",
"    </a>",
"    ]. In one case series, donor antibodies directed against cognate recipient antigens were identified less frequently in TRALI cases involving only RBC transfusions (18 percent) than in cases involving FFP (82 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/18\">",
"     18",
"    </a>",
"    ]. Two subsequent analyses found that TRALI cases associated with RBC transfusion were not correlated with female or other alloimmunized donors. In contrast, these studies did associate high-plasma volume blood components from female and alloimmunized plasma donors with risk for TRALI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/18,55\">",
"     18,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although RBC mediated TRALI continues to occur, no effective and practical risk reduction measures are available, with the exception of conservative RBC transfusion practices. One retrospective report suggested that leukocyte reduction may have decreased TRALI incidence at a single institution; however, a randomized clinical trial comparing pre-storage leukocyte reduced RBC transfusion with standard allogeneic RBC transfusion found no evidence for differing rates of either early or late",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    in transfused trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. Furthermore, TRALI has been reported in many countries that practice universal leukoreduction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the mechanism for red blood cell-induced TRALI, it has been suggested that the use of younger red blood cells or washed red blood cells would prevent some TRALI cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/119,135\">",
"     119,135",
"    </a>",
"    ]. However, the data on red blood cell age and TRALI are contradictory and unconvincing. Moreover, the only data concerning prevention of TRALI by RBC washing are retrospective and observational. [",
"    <a class=\"abstract\" href=\"UTD.htm?27/39/28282/abstract/39-41,64,119\">",
"     39-41,64,119",
"    </a>",
"    ]. Furthermore, washing large number of red cell units is not logistically feasible for most institutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transfusion-related acute lung injury (TRALI) is a serious respiratory complication of transfusion. It is the leading cause of transfusion-related mortality in the United States. (See",
"      <a class=\"local\" href=\"#H17314915\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TRALI can be seen following transfusion of any type of blood component in any patient. Historically, the blood components most likely to cause TRALI were those with a high concentration of donor plasma (due to antibodies to human leukocyte and human neutrophil antigens). Risk mitigation strategies have dramatically reduced the risk of plasma-associated TRALI, and currently the majority of TRALI cases are associated with transfusion of red blood cells (RBC). (See",
"      <a class=\"local\" href=\"#H1588903\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A \"two-hit\" hypothesis for the pathogenesis of TRALI holds that recipient neutrophils are primed for activation by virtue of the patient's underlying clinical condition. The second hit involves activation of these neutrophils by pre-formed anti-leukocyte antibodies or biological response modifiers contained in the transfused product. In rare cases, the transfused product may provide both hits. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic clinical presentation of TRALI is the sudden onset of hypoxemic respiratory insufficiency during or shortly after the transfusion of a blood product. Patients with TRALI often have frothy airway secretions (if intubated), fever, cyanosis, and hypotension. When TRALI is suspected, the treating physician should evaluate the recipient&rsquo;s vital signs, assess the extent of hypoxemia, and obtain a chest radiograph. Pulse oximetry is often sufficient, but arterial blood gas analysis may be warranted in more severe cases. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TRALI is a clinical diagnosis. It should be considered whenever a patient develops hypoxemic respiratory distress during or within six hours after transfusion of any blood product. The criteria set forth by the United States National Heart, Lung, and Blood Institute and the Canadian Consensus Conference panels should be considered sufficient to establish the diagnosis of TRALI (",
"      <a class=\"graphic graphic_table graphicRef64212 \" href=\"UTD.htm?7/15/7420\">",
"       table 1",
"      </a>",
"      ). These criteria require the presence of",
"      <strong>",
"       new",
"      </strong>",
"      acute lung injury",
"      <span class=\"nowrap\">",
"       (ALI)/acute",
"      </span>",
"      respiratory distress syndrome (ARDS) occurring during or within six hours after blood product administration. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of TRALI includes other conditions that can manifest with respiratory distress following transfusion. This includes other causes of",
"      <span class=\"nowrap\">",
"       ALI/ARDS",
"      </span>",
"      as well as other transfusion reactions. The distinction between TRALI and TACO is important for proper management (",
"      <a class=\"graphic graphic_table graphicRef86939 \" href=\"UTD.htm?20/44/21196\">",
"       table 2",
"      </a>",
"      ). Since a confirmed diagnosis of TRALI has implications for blood suppliers, the term &ldquo;possible TRALI&rdquo; is preferred for patients who meet criteria for TRALI, but have additional risk factors for",
"      <span class=\"nowrap\">",
"       ALI/ARDS.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1592582\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of the patient with TRALI includes immediate discontinuation of the transfusion and reporting to the blood bank that TRALI is suspected. Therapy is supportive with supplemental oxygen and ventilatory support with lung protective strategies when clinically indicated. Clinical improvement should be expected to occur spontaneously as the lung injury resolves, and patients who survive TRALI are expected to recover completely. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17314915\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of TRALI involves deferring donors implicated in a case of TRALI from future platelet apheresis, plasma apheresis, and possibly also whole blood donation. Donations from multiparous women are most likely to contain anti-leukocyte antibodies. Most developed countries have adopted a policy of supplying transfusable plasma products (plasma, platelets, and whole blood) exclusively or predominantly from male donors, female donors with no prior pregnancy, or from donors who test negative for HLA-antibodies. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/1\">",
"      Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004; 44:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/2\">",
"      Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33:721.",
"     </a>",
"    </li>",
"    <li>",
"     Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2011. Available at: file://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm302847.htm (Accessed on December 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/4\">",
"      Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/5\">",
"      Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/6\">",
"      Wallis JP. Transfusion-related acute lung injury (TRALI)--under-diagnosed and under-reported. Br J Anaesth 2003; 90:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/7\">",
"      Rana R, Fern&aacute;ndez-P&eacute;rez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion 2006; 46:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/8\">",
"      Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009; 49:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/9\">",
"      Kopko PM, Marshall CS, MacKenzie MR, et al. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002; 287:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/10\">",
"      Vlaar AP, Wortel K, Binnekade JM, et al. The practice of reporting transfusion-related acute lung injury: a national survey among clinical and preclinical disciplines. Transfusion 2010; 50:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/11\">",
"      Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010; 50:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/12\">",
"      Vlaar AP, Binnekade JM, Prins D, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med 2010; 38:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/13\">",
"      Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 2007; 176:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/14\">",
"      Finlay HE, Cassorla L, Feiner J, Toy P. Designing and testing a computer-based screening system for transfusion-related acute lung injury. Am J Clin Pathol 2005; 124:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/15\">",
"      Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012; 119:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/16\">",
"      Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest 2004; 126:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/17\">",
"      Vlaar AP, Hofstra JJ, Determann RM, et al. The incidence, risk factors, and outcome of transfusion-related acute lung injury in a cohort of cardiac surgery patients: a prospective nested case-control study. Blood 2011; 117:4218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/18\">",
"      van Stein D, Beckers EA, Sintnicolaas K, et al. Transfusion-related acute lung injury reports in the Netherlands: an observational study. Transfusion 2010; 50:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/19\">",
"      Keller-Stanislawski B, Reil A, G&uuml;nay S, Funk MB. Frequency and severity of transfusion-related acute lung injury--German haemovigilance data (2006-2007). Vox Sang 2010; 98:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/20\">",
"      Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev 2004; 18:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/21\">",
"      Popovsky MA, Chaplin HC Jr, Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion 1992; 32:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/22\">",
"      Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood 2005; 105:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/23\">",
"      Silliman CC, Paterson AJ, Dickey WO, et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion 1997; 37:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/24\">",
"      Gajic O, Rana R, Mendez JL, et al. Acute lung injury after blood transfusion in mechanically ventilated patients. Transfusion 2004; 44:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/25\">",
"      Toy P, Gajic O. Transfusion-related acute lung injury. Anesth Analg 2004; 99:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/26\">",
"      Watkins TR, Cooke CR, Hudson LD, et al. Transfusion and lung injury: The role of red blood cell storage time. Crit Care Med 2007; 35:A159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/27\">",
"      Benson AB, Austin GL, Berg M, et al. Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleeding. Intensive Care Med 2010; 36:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/28\">",
"      Sachs UJ, Bux J. TRALI after the transfusion of cross-match-positive granulocytes. Transfusion 2003; 43:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/29\">",
"      Suassuna JH, da Costa MA, Faria RA, Melichar AC. Noncardiogenic pulmonary edema triggered by intravenous immunoglobulin in cancer-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Nephron 1997; 77:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/30\">",
"      Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001; 41:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/31\">",
"      Boshkov LK. Transfusion-related acute lung injury and the ICU. Crit Care Clin 2005; 21:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/32\">",
"      Ozier Y, Muller JY, Mertes PM, et al. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. Transfusion 2011; 51:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/33\">",
"      Win N, Chapman CE, Bowles KM, et al. How much residual plasma may cause TRALI? Transfus Med 2008; 18:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/34\">",
"      Palfi M, Berg S, Ernerudh J, Berlin G. A randomized controlled trial oftransfusion-related acute lung injury: is plasma from multiparous blood donors dangerous? Transfusion 2001; 41:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/35\">",
"      Wright SE, Snowden CP, Athey SC, et al. Acute lung injury after ruptured abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh frozen plasma. Crit Care Med 2008; 36:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/36\">",
"      Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med 2007; 35:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/37\">",
"      Toy P, Hollis-Perry KM, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA antibodies: a lookback study of transfusion-related acute lung injury. Transfusion 2004; 44:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/38\">",
"      Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/39\">",
"      Kor DJ, Kashyap R, Weiskopf RB, et al. Fresh red blood cell transfusion and short-term pulmonary, immunologic, and coagulation status: a randomized clinical trial. Am J Respir Crit Care Med 2012; 185:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/40\">",
"      Weiskopf RB, Feiner J, Toy P, et al. Fresh and stored red blood cell transfusion equivalently induce subclinical pulmonary gas exchange deficit in normal humans. Anesth Analg 2012; 114:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/41\">",
"      Edgren G, Kamper-J&oslash;rgensen M, Eloranta S, et al. Duration of red blood cell storage and survival of transfused patients (CME). Transfusion 2010; 50:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/42\">",
"      Silliman CC. The two-event model of transfusion-related acute lung injury. Crit Care Med 2006; 34:S124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/43\">",
"      Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007; 136:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/44\">",
"      Fung YL, Silliman CC. The role of neutrophils in the pathogenesis of transfusion-related acute lung injury. Transfus Med Rev 2009; 23:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/45\">",
"      Bux J. Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sang 2005; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/46\">",
"      Sachs UJ. Pathophysiology of TRALI: current concepts. Intensive Care Med 2007; 33 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/47\">",
"      Jutzi M, Levy G, Taleghani BM. Swiss Haemovigilance Data and Implementation of Measures for the Prevention of Transfusion Associated Acute Lung Injury (TRALI). Transfus Med Hemother 2008; 35:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/48\">",
"      Tamarozzi MB, Soares SG, S&aacute;-Nunes A, et al. Comparative analysis of the pathological events involved in immune and non-immune TRALI models. Vox Sang 2012; 103:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/49\">",
"      Kleinman SH, Triulzi DJ, Murphy EL, et al. The Leukocyte Antibody Prevalence Study-II (LAPS-II): a retrospective cohort study of transfusion-related acute lung injury in recipients of high-plasma-volume human leukocyte antigen antibody-positive or -negative components. Transfusion 2011; 51:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/50\">",
"      Cooling L. Transfusion-related acute lung injury. JAMA 2002; 288:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/51\">",
"      Win N, Ranasinghe E, Lucas G. Transfusion-related acute lung injury: a 5-year look-back study. Transfus Med 2002; 12:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/52\">",
"      Nicolle AL, Chapman CE, Carter V, Wallis JP. Transfusion-related acute lung injury caused by two donors with anti-human leucocyte antigen class II antibodies: a look-back investigation. Transfus Med 2004; 14:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/53\">",
"      Curtis BR, Cox NJ, Sullivan MJ, et al. The neutrophil alloantigen HNA-3a (5b) is located on choline transporter-like protein 2 and appears to be encoded by an R&gt;Q154 amino acid substitution. Blood 2010; 115:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/54\">",
"      Dykes A, Smallwood D, Kotsimbos T, Street A. Transfusion-related acute lung injury (Trali) in a patient with a single lung transplant. Br J Haematol 2000; 109:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/55\">",
"      Middelburg RA, Van Stein D, Zupanska B, et al. Female donors and transfusion-related acute lung injury: A case-referent study from the International TRALI Unisex Research Group. Transfusion 2010; 50:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/56\">",
"      Middelburg RA, van Stein D, Atsma F, et al. Alloexposed blood donors and transfusion-related acute lung injury: a case-referent study. Transfusion 2011; 51:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/57\">",
"      Middelburg RA, van Stein D, Bri&euml;t E, van der Bom JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion 2008; 48:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/58\">",
"      Bux J. Antibody-mediated (immune) transfusion-related acute lung injury. Vox Sang 2011; 100:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/59\">",
"      Sachs UJ. Recent insights into the mechanism of transfusion-related acute lung injury. Curr Opin Hematol 2011; 18:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/60\">",
"      Sachs UJ, Hattar K, Weissmann N, et al. Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. Blood 2006; 107:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/61\">",
"      Seeger W, Schneider U, Kreusler B, et al. Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood 1990; 76:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/62\">",
"      Looney MR, Nguyen JX, Hu Y, et al. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119:3450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/63\">",
"      Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest 1998; 101:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/64\">",
"      Kelher MR, Masuno T, Moore EE, et al. Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. Blood 2009; 113:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/65\">",
"      Looney MR, Su X, Van Ziffle JA, et al. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest 2006; 116:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/66\">",
"      Thompson JS, Severson CD, Parmely MJ, et al. Pulmonary \"hypersensitivity\" reactions induced by transfusion of non-HL-A leukoagglutinins. N Engl J Med 1971; 284:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/67\">",
"      Flesch BK, Neppert J. Transfusion-related acute lung injury caused by human leucocyte antigen class II antibody. Br J Haematol 2002; 116:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/68\">",
"      BRITTINGHAM TE. Immunologic studies on leukocytes. Vox Sang 1957; 2:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/69\">",
"      Nakagawa M, Toy P. Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital. Transfusion 2004; 44:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/70\">",
"      Marques MB, Tuncer HH, Divers SG, et al. Acute transient leukopenia as a sign of TRALI. Am J Hematol 2005; 80:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/71\">",
"      Dry SM, Bechard KM, Milford EL, et al. The pathology of transfusion-related acute lung injury. Am J Clin Pathol 1999; 112:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/72\">",
"      Curtis BR, McFarland JG. Mechanisms of transfusion-related acute lung injury (TRALI): anti-leukocyte antibodies. Crit Care Med 2006; 34:S118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/73\">",
"      Kopko PM, Popovsky MA, MacKenzie MR, et al. HLA class II antibodies in transfusion-related acute lung injury. Transfusion 2001; 41:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/74\">",
"      Densmore TL, Goodnough LT, Ali S, et al. Prevalence of HLA sensitization in female apheresis donors. Transfusion 1999; 39:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/75\">",
"      Triulzi DJ, Kakaiya R, Schreiber G. Donor risk factors for white blood cell antibodies associated with transfusion-associated acute lung injury: REDS-II leukocyte antibody prevalence study (LAPS). Transfusion 2007; 47:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/76\">",
"      Davoren A, Curtis BR, Shulman IA, et al. TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion 2003; 43:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/77\">",
"      Reil A, Keller-Stanislawski B, G&uuml;nay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008; 95:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/78\">",
"      Sachs UJ, Wasel W, Bayat B, et al. Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood 2011; 117:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/79\">",
"      Nishimura M, Hashimoto S, Takanashi M, et al. Role of anti-human leucocyte antigen class II alloantibody and monocytes in development of transfusion-related acute lung injury. Transfus Med 2007; 17:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/80\">",
"      Wakamoto S, Fujihara M, Takahashi D, et al. Enhancement of endothelial permeability by coculture with peripheral blood mononuclear cells in the presence of HLA Class II antibody that was associated with transfusion-related acute lung injury. Transfusion 2011; 51:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/81\">",
"      Silliman CC, Bjornsen AJ, Wyman TH, et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion 2003; 43:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/82\">",
"      Silliman CC, Moore EE, Kelher MR, et al. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion 2011; 51:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/83\">",
"      Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006; 108:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/84\">",
"      Andrews AT, Zmijewski CM, Bowman HS, Reihart JK. Transfusion reaction with pulmonary infiltration associated with HL-A-specific leukocyte antibodies. Am J Clin Pathol 1976; 66:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/85\">",
"      Yomtovian R, Kline W, Press C, et al. Severe pulmonary hypersensitivity associated with passive transfusion of a neutrophil-specific antibody. Lancet 1984; 1:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/86\">",
"      Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol 2007; 14:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/87\">",
"      Popovsky MA. Transfusion-associated circulatory overload: the plot thickens. Transfusion 2009; 49:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/88\">",
"      Zhou L, Giacherio D, Cooling L, Davenport RD. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion 2005; 45:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/89\">",
"      Tobian AA, Sokoll LJ, Tisch DJ, et al. N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload. Transfusion 2008; 48:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/90\">",
"      Li G, Daniels CE, Kojicic M, et al. The accuracy of natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in the differentiation between transfusion-related acute lung injury and transfusion-related circulatory overload in the critically ill. Transfusion 2009; 49:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/91\">",
"      Rice TW, Ware LB, Haponik EF, et al. Vascular pedicle width in acute lung injury: correlation with intravascular pressures and ability to discriminate fluid status. Crit Care 2011; 15:R86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/92\">",
"      Ely EW, Smith AC, Chiles C, et al. Radiologic determination of intravascular volume status using portable, digital chest radiography: a prospective investigation in 100 patients. Crit Care Med 2001; 29:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/93\">",
"      Gajic O, Gropper MA, Hubmayr RD. Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. Crit Care Med 2006; 34:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/94\">",
"      Popovsky MA. The Emily Cooley Lecture 2009 To breathe or not to breathe-that is the question. Transfusion 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/95\">",
"      National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/96\">",
"      ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307:2526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/97\">",
"      Wallis JP, Lubenko A, Wells AW, Chapman CE. Single hospital experience of TRALI. Transfusion 2003; 43:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/98\">",
"      Goldberg AD, Kor DJ. State of the art management of transfusion-related acute lung injury (TRALI). Curr Pharm Des 2012; 18:3273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/99\">",
"      Worsley MH, Sinclair CJ, Campanella C, et al. Non-cardiogenic pulmonary oedema after transfusion with granulocyte antibody containing blood: treatment with extracorporeal membrane oxygenation. Br J Anaesth 1991; 67:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/100\">",
"      Wallis JP. Transfusion-related acute lung injury (TRALI): presentation, epidemiology and treatment. Intensive Care Med 2007; 33 Suppl 1:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/101\">",
"      Levy GJ, Shabot MM, Hart ME, et al. Transfusion-associated noncardiogenic pulmonary edema. Report of a case and a warning regarding treatment. Transfusion 1986; 26:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/102\">",
"      Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008; 336:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/103\">",
"      Tang BM, Craig JC, Eslick GD, et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med 2009; 37:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/104\">",
"      Jeddi R, Mansouri R, Kacem K, et al. Transfusion-related acute lung injury (TRALI) during remission induction course of acute myeloid leukemia: a possible role for all-transretinoic-acid (ATRA)? Pathol Biol (Paris) 2009; 57:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/105\">",
"      Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/106\">",
"      O'Neal HR Jr, Koyama T, Koehler EA, et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 2011; 39:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/107\">",
"      Kor DJ, Erlich J, Gong MN, et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med 2011; 39:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/108\">",
"      Nordhagen R, Conradi M, Dr&ouml;mtorp SM. Pulmonary reaction associated with transfusion of plasma containing anti-5b. Vox Sang 1986; 51:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/109\">",
"      Reissman P, Manny N, Shapira SC, et al. Transfusion-related adult respiratory distress syndrome. Isr J Med Sci 1993; 29:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/110\">",
"      Eastlund T, McGrath PC, Britten A, Propp R. Fatal pulmonary transfusion reaction to plasma containing donor HLA antibody. Vox Sang 1989; 57:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/111\">",
"      Win N, Montgomery J, Sage D, et al. Recurrent transfusion-related acute lung injury. Transfusion 2001; 41:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/112\">",
"      Silliman CC, Fung YL, Ball JB, Khan SY. Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. Blood Rev 2009; 23:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/113\">",
"      ISBT Working Party on Granulocyte Immunobiology, Bierling P, Bux J, et al. Recommendations of the ISBT Working Party on Granulocyte Immunobiology for leucocyte antibody screening in the investigation and prevention of antibody-mediated transfusion-related acute lung injury. Vox Sang 2009; 96:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/114\">",
"      Su L, Kamel H. How do we investigate and manage donors associated with a suspected case of transfusion-related acute lung injury. Transfusion 2007; 47:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/115\">",
"      Mair DC, Hirschler N, Eastlund T. Blood donor and component management strategies to prevent transfusion-related acute lung injury (TRALI). Crit Care Med 2006; 34:S137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/116\">",
"      Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007; 47:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/117\">",
"      Insunza A, Romon I, Gonzalez-Ponte ML, et al. Implementation of a strategy to prevent TRALI in a regional blood centre. Transfus Med 2004; 14:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/118\">",
"      Wendel S, Biagini S, Trigo F, et al. Measures to prevent TRALI. Vox Sang 2007; 92:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/119\">",
"      Reesink HW, Lee J, Keller A, et al. Measures to prevent transfusion-related acute lung injury (TRALI). Vox Sang 2012; 103:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/120\">",
"      Lucas G, Win N, Calvert A, et al. Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines. Vox Sang 2012; 103:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/121\">",
"      Kleinman S, Grossman B, Kopko P. A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States. Transfusion 2010; 50:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/122\">",
"      Sachs UJ, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 2005; 45:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/123\">",
"      Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003; 85:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/124\">",
"      Sinnott P, Bodger S, Gupta A, Brophy M. Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Eur J Immunogenet 2004; 31:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/125\">",
"      Powers A, Stowell CP, Dzik WH, et al. Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion 2008; 48:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/126\">",
"      Carrick DM, Norris PJ, Endres RO, et al. Establishing assay cutoffs for HLA antibody screening of apheresis donors. Transfusion 2011; 51:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/127\">",
"      Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009; 49:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/128\">",
"      Murphy MF, Navarrete C, Massey E. Donor screening as a TRALI risk reduction strategy. Transfusion 2009; 49:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/129\">",
"      Tynell E, Andersson TM, Norda R, et al. Should plasma from female donors be avoided? A population-based cohort study of plasma recipients in Sweden from 1990 through 2002. Transfusion 2010; 50:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/130\">",
"      Kakaiya RM, Triulzi DJ, Wright DJ, et al. Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors. Transfusion 2010; 50:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/131\">",
"      Funk MB, Guenay S, Lohmann A, et al. Benefit of transfusion-related acute lung injury risk-minimization measures--German haemovigilance data (2006-2010). Vox Sang 2012; 102:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/132\">",
"      Lin Y, Saw CL, Hannach B, Goldman M. Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. Transfusion 2012; 52:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/133\">",
"      Blumberg N, Heal JM, Gettings KF, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion 2010; 50:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/134\">",
"      Watkins TR, Rubenfeld GD, Martin TR, et al. Effects of leukoreduced blood on acute lung injury after trauma: a randomized controlled trial. Crit Care Med 2008; 36:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/39/28282/abstract/135\">",
"      Biffl WL, Moore EE, Offner PJ, et al. Plasma from aged stored red blood cells delays neutrophil apoptosis and primes for cytotoxicity: abrogation by poststorage washing but not prestorage leukoreduction. J Trauma 2001; 50:426.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7926 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28282=[""].join("\n");
var outline_f27_39_28282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1588903\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1588910\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1588938\">",
"      Recipient risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17014590\">",
"      Blood component risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1592582\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17314495\">",
"      Possible TRALI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17314533\">",
"      TACO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13037582\">",
"      Other causes of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1592784\">",
"      Other transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11655881\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11655890\">",
"      Ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11655897\">",
"      Hemodynamic support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11655904\">",
"      Steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11655911\">",
"      Investigational strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11655918\">",
"      Additional transfusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17314915\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11655925\">",
"      Deferral of multiparous female donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11655932\">",
"      Use of solvent detergent treated plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11655939\">",
"      Mitigating TRALI risk from platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11655954\">",
"      Mitigating TRALI risk from RBC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7926\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7926|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/15/7420\" title=\"table 1\">",
"      TRALI diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/44/21196\" title=\"table 2\">",
"      Distinguishing TRALI and TACO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4500?source=related_link\">",
"      Solvent detergent treated fresh frozen plasma: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_39_28283="Eligibility criteria for auto-HCT";
var content_f27_39_28283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General eligibility criteria for autologous hematopoietic cell transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Disease-related indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Karnofsky performance status &ge;70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Renal function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Serum creatinine &lt;2 mg/dL (177 micromol/L), unless autologous HCT is for myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cardiac reserve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        LVEF &ge;40 percent if using the BEAM conditioning regimen and a LVEF &ge;50 percent using chemotherapy regimens with known cardiac toxicity (eg, cyclophosphamide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pulmonary function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        A corrected DLCO &ge;50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Liver function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No frank cirrhosis of the liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adequate psychosocial and financial support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No evidence of myelodysplasia on bone marrow examination",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HCT: hematopoietic cell transplantation; LVEF: left ventricular ejection fraction; BEAM: BCNU, etoposide, cytarabine, and melphalan; DLCO: diffusing capacity of the lungs for carbon monoxide.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28283=[""].join("\n");
var outline_f27_39_28283=null;
var title_f27_39_28284="Risk of retinoblastoma in offspring and siblings";
var content_f27_39_28284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric risks for development of retinoblastoma in offspring and siblings of a proband when an RB1 germline mutation has not been identified",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Tumor presentation in index case",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Family history",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Risk to offspring of an index case",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Risk to sibs of an index case",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Bilateral",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Unilateral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Multifocal",
"       </td>",
"       <td class=\"subtitle3\">",
"        Unifocal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        2 percent*",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        1 to 2 percent*",
"       </td>",
"       <td>",
"        6 to 50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        ~1 percent*",
"       </td>",
"       <td>",
"        6 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        Variable",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Variable",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"       <td>",
"        50 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If there is no unaffected sibling. (Draper GJ, Sanders BM, Brownbill PA, Hawkins MM. Patterns of risk of hereditary retinoblastoma and applications to genetic counselling. Br J Cancer 1992; 66:211).",
"     <br>",
"      &bull; In families with unilateral retinoblastoma, penetrance varies widely.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lohmann DR, Gallie BL. Retinoblastoma. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright &copy; University of Washington, Seattle. 1997-2012. Available at:&nbsp;",
"     <a href=\"file://www.ncbi.nlm.nih.gov/books/NBK1452/\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      www.ncbi.nlm.nih.gov/books/NBK1452/",
"     </a>",
"     (Accessed on February 16, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28284=[""].join("\n");
var outline_f27_39_28284=null;
var title_f27_39_28285="Causes acute respiratory distress in children";
var content_f27_39_28285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of acute respiratory compromise in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respiratory tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Uvulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span class=\"red\">",
"         Epiglottitis",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Retropharyngeal abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Peritonsillar abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Croup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tracheitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bronchiolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"red\">",
"         Anaphylaxis",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign body (",
"        <span style=\"color: #ff0000;\">",
"         upper airway",
"        </span>",
"        , lower airway, esophagus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway anomalies (eg, laryngomalacia, laryngospasm, tracheoesophageal fistula, tracheal stenosis, tracheal ring or sling)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Biologic or chemical weapons",
"        </span>",
"        (eg, anthrax, tularemia, phosgene, nitrogen mustard, nerve agents, ricin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest wall trauma or abnormalities (eg,",
"        <span style=\"color: #ff0000;\">",
"         flail chest",
"        </span>",
"        ,",
"        <span style=\"color: #ff0000;\">",
"         open pneumothorax",
"        </span>",
"        , thoracic dystrophy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic cavity trauma or conditions (eg,",
"        <span style=\"color: #ff0000;\">",
"         pneumothorax",
"        </span>",
"        ,",
"        <span style=\"color: #ff0000;\">",
"         hemothorax",
"        </span>",
"        , pleural effusion, empyema, mediastinal mass)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary trauma or conditions (contusion, embolism, hemorrhage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Smoke inhalation",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Chemical agent exposures",
"        </span>",
"        (eg,",
"        <span style=\"color: #ff0000;\">",
"         phosgene",
"        </span>",
"        ,",
"        <span style=\"color: #ff0000;\">",
"         chlorine",
"        </span>",
"        ,",
"        <span style=\"color: #ff0000;\">",
"         cyanide",
"        </span>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Submersion injury (near-drowning)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute decompensated heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Shock",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         Cardiac tamponade",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depressed ventilation (eg, ingestion,",
"        <span style=\"color: #ff0000;\">",
"         CNS trauma",
"        </span>",
"        , seizures, or CNS infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotonia (conditions causing poor airway or respiratory muscle tone and ineffective respiratory effort)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary aspiration due to loss of airway protective reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoventilation due to abdominal pain or distention (eg, intraabdominal trauma, small bowel obstruction, bowel perforation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastroesophageal reflux with pulmonary aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Metabolic and endocrine diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic acidosis (eg, diabetic ketoacidosis, severe dehydration, sepsis, toxic ingestions, inborn errors of metabolism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperammonemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypocalcemia (laryngospasm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hematologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased O2 carrying capacity (eg, acute severe anemia from hemolysis, methemoglobinemia, carbon monoxide poisoning)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute chest syndrome (patients with sickle cell disease)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Conditions listed in",
"    <span class=\"red\">",
"     red",
"    </span>",
"    are immediately life threatening.",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; O2: oxygen.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28285=[""].join("\n");
var outline_f27_39_28285=null;
var title_f27_39_28286="VMP for multiple myeloma";
var content_f27_39_28286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bortezomib (Velcade) plus melphalan and prednisone (VMP) for multiple myeloma",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 35 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bortezomib",
"        </strong>",
"       </td>",
"       <td>",
"        1.3 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV or SC",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        Given subcutaneously or as a rapid IV bolus over three to five seconds.",
"       </td>",
"       <td>",
"        Days 1, 8, 15, and 22*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Melphalan",
"        </strong>",
"       </td>",
"       <td>",
"        9 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        by mouth, daily",
"       </td>",
"       <td>",
"        Take on an empty stomach (one hour prior to, or two hours after a meal).",
"       </td>",
"       <td>",
"        Cycles 1 through 9: Days 1 through 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prednisone",
"        </strong>",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        by mouth, daily",
"       </td>",
"       <td>",
"        Take with food (after meals or with food or milk) in the morning.",
"       </td>",
"       <td>",
"        Cycles 1 through 9: Days 1 through 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        LOW or VERY LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Routine premedication is not indicated. If a hypersensitivity reaction occurs with melphalan, then neither oral nor IV melphalan should not be readministered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Antithrombotic prophylaxis:",
"        </strong>",
"        While patients with multiple myeloma have an increased risk of thrombosis, the risk of thrombosis with the VMP regimen was 1 and 2 percent in two trials",
"        <sup>",
"         [1,3]",
"        </sup>",
"        . Routine antithrombotic prophylaxis is not warranted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Bortezomib therapy may be associated with an increased risk of herpes zoster and infections not related to neutropenia. Antiviral prophylaxis (eg, acyclovir 400 mg orally twice a day) should be administered to all patients receiving VMP. Primary prophylaxis with G-CSF not indicated (rate of severe infection 9 percent)",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        <p>",
"         &bull;",
"         <strong>",
"          Dose adjustment for baseline liver or renal dysfunction:",
"         </strong>",
"         The US FDA-approved manufacturer's labeling for melphalan provides no specific recommendation for melphalan dose modification in patients with renal dysfunction",
"         <sup>",
"          [4]",
"         </sup>",
"         . Some clinicians recommend a 25 percent reduction in the initial dose of oral melphalan for patients with multiple myeloma and a serum creatinine &gt;2 mg/dL to prevent severe myelotoxicity",
"         <sup>",
"          [5]",
"         </sup>",
"         . If myelotoxicity does not occur, standard doses should be administered in the subsequent courses. Administer melphalan after hemodialysis in patients undergoing hemodialysis. No dose adjustment for melphalan is necessary in patients with hepatic insufficiency.",
"        </p>",
"        <p>",
"         No dosage adjustment for bortezomib secondary to renal insufficiency is necessary",
"         <sup>",
"          [6]",
"         </sup>",
"         . For patients undergoing hemodialysis, bortezomib should be administered after dialysis.",
"        </p>",
"        <p>",
"         Patients with moderate or severe hepatic impairment (serum bilirubin level &gt;1.5 times the upper limit of normal) should be started on bortezomib at a reduced dose of 0.7 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         per injection during the first cycle, with further dose modifications based upon patient tolerance. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess CBC with differential, electrolytes, renal function, liver function, and M protein prior to starting each cycle. A CBC should also be performed prior to the day 11 dose of bortezomib during induction therapy and day 15 dose of bortezomib during maintenance therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Weekly assessment for peripheral neuropathy and/or neuropathic pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hypotension during therapy; adjustment of antihypertensives and/or administration of IV hydration may be needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        A cycle of VMP should not be started unless the ANC is &ge;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and the platelet count is &ge;70,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        <sup>",
"         [6]",
"        </sup>",
"        . If prolonged grade 4 neutropenia (ANC &lt;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        ), any grade 4 thrombocytopenia (platelet count &lt;25,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        ), or thrombocytopenia with bleeding are observed, consider a 25 percent reduction of the melphalan dose for subsequent cycles. If platelets are &lt;30,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        or ANC is &lt;750 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        on day 15, hold bortezomib. If several doses are held, reduce bortezomib dose by one level (from 1.3 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        to 1 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        or from 1 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        to 0.7 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neuropathy:",
"        </strong>",
"        Dose adjustment guidelines for bortezomib in patients who develop peripheral neuropathy or neuropathic pain are available",
"        <sup>",
"         [6]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        - Grade 1 (asymptomatic, loss of deep tendon reflexes or paresthesia without pain or loss of function)",
"       </td>",
"       <td>",
"        No action required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        - Grade 1 (with pain) or Grade 2 (interfering function but not activities of daily living)",
"       </td>",
"       <td>",
"        Reduce to 1 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        - Grade 2 (with pain) or Grade 3 (interfering with activities of daily living)",
"       </td>",
"       <td>",
"        Hold until resolution, may reinitiate at 0.7 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        once weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        - Grade 4 (life-threatening, disabling, eg, paralysis)",
"       </td>",
"       <td>",
"        Discontinue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Rates of neuropathy may be lower with subcutaneous administration of bortezomib",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other nonhematological toxicity:",
"        </strong>",
"        For grade 3 or 4 nonhematologic toxicity other than neuropathy, bortezomib should be held. Once symptoms have resolved to grade 1 or baseline, bortezomib may be reinitiated with one dose level reduction (from 1.3 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        to 1 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , or from 1 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        to 0.7 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        ).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; SC: subcutaneous; G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count.",
"     <br/>",
"     * Some investigators administer the first cycle of bortezomib using a twice-weekly schedule, especially in patients in whom a rapid response is needed",
"     <sup>",
"      [7]",
"     </sup>",
"     : days 1, 4, 8, 11, 22, 25, 29, and 32 of a six week cycle, with melphalan and prednisone administered in the usual dose on days 1 through 4 of that cycle.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Palumbo A, et al. J Clin Oncol 2010; 28:5101.",
"      </li>",
"      <li>",
"       Moreau P, et al. Lancet Oncol 2011; 12:431.",
"      </li>",
"      <li>",
"       San Miguel JF, et al. N Eng J Med 2008; 359:906.",
"      </li>",
"      <li>",
"       Alkeran (melphalan). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).",
"      </li>",
"      <li>",
"       Carlson K, et al. Br J Haematol 2005; 128:631.",
"      </li>",
"      <li>",
"       Velcade (bortezomib) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).",
"      </li>",
"      <li>",
"       Mateos MV, et al. Lancet Oncol 2010; 11:934.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28286=[""].join("\n");
var outline_f27_39_28286=null;
var title_f27_39_28287="XLH rickets radiograph";
var content_f27_39_28287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    XLH rickets radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 282px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Standing anteroposterior films of both lower extremities help distinguish physiologic bowing from pathologic causes. This patient with X-linked hypophosphatemic rickets (XLH) has multiple widened physes. Osteopenia is evident in the adjacent metaphysis, which is also flared. Bowing tends to be more diffuse throughout the bone, rather than focal in the proximal tibia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schoenecker PL, Rich MM. The Lower Extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Willims &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_39_28287=[""].join("\n");
var outline_f27_39_28287=null;
